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SUMMARY
Sixteen ovarian tumor (OTU) family deubiquitinases
(DUBs) exist in humans, and most members regulate
cell-signaling cascades. Several OTU DUBs were
reported to be ubiquitin (Ub) chain linkage speciﬁc,
but comprehensive analyses are missing, and the
underlying mechanisms of linkage speciﬁcity are
unclear. Using Ub chains of all eight linkage types,
we reveal that most human OTU enzymes are linkage
speciﬁc, preferring one, two, or a deﬁned subset of
linkage types, including unstudied atypical Ub
chains. Biochemical analysis and ﬁve crystal struc-
tures of OTU DUBs with or without Ub substrates
reveal four mechanisms of linkage speciﬁcity. Addi-
tional Ub-binding domains, the ubiquitinated
sequence in the substrate, and deﬁned S1’ and
S2 Ub-binding sites on the OTU domain enable
OTU DUBs to distinguish linkage types. We intro-
duce Ub chain restriction analysis, in which OTU
DUBs are used as restriction enzymes to reveal
linkage type and the relative abundance of Ub chains
on substrates.
INTRODUCTION
Protein ubiquitination is a posttranslational modiﬁcation of
mostly Lys residues that regulates many cellular processes,
including protein degradation, intracellular trafﬁcking, cell
signaling, autophagy, transcription, translation, and the DNA
damage response (Komander and Rape, 2012). This functional
diversity is achieved by the ability of ubiquitin (Ub) to form
topologically distinct signals. Proteins can be monoubiquiti-
nated at one or multiple sites or polyubiquitinated by modiﬁca-
tion with Ub chains. Within Ub chains, linkages can be formed
via seven Ub Lys residues or via the N-terminal Met1, gener-
ating homotypic (one linkage type per polymer) or heterotypic
(multiple linkage types per polymer) Ub chains (Komander
and Rape, 2012). Differently linked Ub polymers have distinct
cellular functions. Lys48-linked Ub chains serve as a pro-
teasomal degradation signal (Hershko and Ciechanover,
1998), whereas Lys63-linked chains are nondegradative and,
for example, activate protein kinase cascades (Chen and Sun,
2009). Lys11 linkages constitute an alternative degradation
signal used during cell-cycle progression (Wickliffe et al.,
2011). Met1-linked chains cooperate with Lys63 linkages in
NF-kB signaling (Iwai, 2011). For the remaining four Ub chain
types (Lys6, Lys27, Lys29, and Lys33), cellular roles are elusive
(Kulathu and Komander, 2012).
Deubiquitinases (DUBs) remove Ub modiﬁcations and regu-
late virtually all Ub-dependent processes (Komander et al.,
2009; Reyes-Turcu et al., 2009). Many of the 80 DUBs that
are predicted to be active in human cells have been implicated
in human diseases such as neurodegeneration, inﬂammation,
infection, and cancer (Clague et al., 2012). The subfamily
of ovarian tumor (OTU) DUBs have emerged as regulators of
important signaling cascades. A20 (Hymowitz and Wertz,
2010), OTUD7B/Cezanne (Hu et al., 2013) and OTULIN (Keuse-
kotten et al., 2013) regulate NF-kB signaling, OTUD5/DUBA reg-
ulates interferon signaling (Kayagaki et al., 2007), OTUD2/YOD1
and VCPIP regulate p97-mediated processes (Ernst et al., 2009;
Wang et al., 2004), and OTUB1 is involved in the DNA damage
response (Nakada et al., 2010).
Because of the complexity of the Ub modiﬁcation, DUBs must
display various layers of speciﬁcity—they must distinguish not
only between Ub and Ub-like modiﬁcations but also between
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170 Cell 154, 169–184, July 3, 2013 ª2013 The Authorsthe eight Ub linkage types. Moreover, chain topology and length
may also affect DUB activity (Komander et al., 2009).
The extent to which DUBs are linkage speciﬁc is not clear.
Characterized Ub-speciﬁc protease (USP) family DUBs are not
linkage speciﬁc (Faesen et al., 2011). In contrast, OTU family
DUBs can be linkage speciﬁc. OTUB1 prefers Lys48 linkages
(Edelmann et al., 2009; Wang et al., 2009), Cezanne prefers
Lys11 linkages (Bremm et al., 2010), TRABID is Lys29 and
Lys33 speciﬁc (Licchesi et al., 2012), and OTULIN is Met1 spe-
ciﬁc (Keusekotten et al., 2013). However, with the exception of
TRABID and OTULIN, comprehensive analyses comparing all
chain types have not been performed.
Here, we provide a biochemical characterization of all 16
human OTU DUBs that contain a complete catalytic triad
and analyze their cross-reactivity against Ub-like molecules,
catalytic activity, and linkage speciﬁcity. Most OTU DUBs
show intrinsic linkage speciﬁcity, preferring one or a small
deﬁned subset of Ub linkage types. Mechanistic and structural
studies of three closely related, unstudied OTUs with distinct
cleavage proﬁles revealed four mechanisms for achieving
linkage speciﬁcity, namely (1) the use of additional Ub-binding
domains (UBDs), (2) speciﬁc recognition of a ubiquitinated
sequence, (3) the use of a conserved S1’ Ub-binding site on
the OTU domain itself, and (4) the use of an S2 site enabling
DUBs to bind longer chains in a linkage-speciﬁc manner. The
linkage speciﬁcity in OTU DUBs can be exploited in Ub chain
restriction analysis, whereby linkage-speciﬁc DUBs are used
to identify the linkage type(s) on a ubiquitinated protein.
RESULTS
The Human OTU Enzymes
In the human genome, OTU domains exist in at least 18 genes,
14 of which have been annotated as active DUBs (Komander
et al., 2009). In addition to these, OTULIN/FAM105B (Keusekot-
tenetal.,2013)andALG13(UniProtQ9NP73)haverecentlybeen
described or annotated as additional OTU domains with a com-
plete catalytic triad. FAM105A (UniProt Q9NUU6) contains an
OTULIN-like OTU domain but lacks catalytic triad residues.
HIN1L is a pseudogene (http://www.ncbi.nlm.nih.gov/gene/
360227). Phylogenetic analysis delineates four subfamilies:
the OTUB subfamily/Otubains (OTUB1 and OTUB2), the OTUD
subfamily (OTUD1, OTUD2/YOD1, OTUD3, OTUD4, OTUD5/
DUBA, OTUD6A, OTUD6B, ALG13, and HIN1L), the A20-like
subfamily (A20, Cezanne, Cezanne2, TRABID, and VCPIP), and
the OTULIN subfamily (OTULIN and FAM105A) (Figure 1A). The
size of the catalytic domain distinguishes subfamilies—OTUD
enzymes being the smallest (150 amino acids [aa]), and the
OTUB/OTULIN (220–270 aa) and A20-like OTUs (300–350 aa)
containing larger catalytic folds. Most human OTUs contain
additional domains, including UBDs (Figure 1B).
We cloned the 16 catalytic-triad-containing human OTU
DUBs from plasmids, IMAGE clones, or human complementary
DNA (cDNA) libraries and expressed and puriﬁed full-length
(FL) and/or OTU domain-containing constructs in E. coli
(Figures 1C and 1D). Most OTUs reacted quantitatively with Ub
propargylamide (Ub-PA) (Ekkebus etal.,2013), indicating proper
folding and a reactive catalytic Cys (Figure 1E, Figure S1A avail-
able online). OTUD5/DUBA required activation by phosphoryla-
tion in the OTU domain by recombinant CK2 to display reactivity
(Huang et al., 2012). OTULIN did not react with Ub-PA because it
requires activation by a proximal Ub for activity (Keusekotten
et al., 2013). ALG13 did not react with Ub-PA, but it did react
with haloalkyl probes, and A20 reacted very slowly and incom-
pletely with all tested probes (Figures 1E, S1A, and S1B).
The C terminus of Ub is important for DUB reactivity (Drag
et al., 2008). The Ub-like modiﬁers ISG15 and NEDD8 have
identical or similar C-terminal sequences, and whereas OTUB1
is Ub speciﬁc (Edelmann et al., 2009), viral OTU domains
(vOTU) can be cross-reactive for Ub and ISG15 (Frias-Staheli
et al., 2007). We found that ISG15-based suicide probes that
modiﬁed vOTU (Akutsu et al., 2011) did not react with human
OTU DUBs (Figure S1C). In contrast, 13 of the 16 human OTU
DUBs were modiﬁed by NEDD8-derived suicide probes to
varying degrees (Figure S1D). However, comparing Ub- and
NEDD8-based peptide substrates in ﬂuorescence polarization
assays (Geurink et al., 2012) (see below) showed that OTU
DUBs only hydrolyzed the Ub-based, but not the NEDD8-based,
substrates under identical conditions (Figure S1E), indicating
that human OTU DUBs are Ub speciﬁc.
Linkage Speciﬁcity of OTU DUBs against Diubiquitin
Next, we analyzed the linkage speciﬁcity of human OTU DUBs
against all eight types of diubiquitin (diUb) (Figure 2A). Time-
course experiments were performed at constant substrate
concentration. Enzymes were used at different concentrations
in order to identify the lowest DUB concentration that resulted
in signiﬁcant cleavage of the preferred chain type(s), indicating
linkage preference of the DUB.
The results of this analysis revealed a striking and unexpected
linkage speciﬁcity of all human OTU DUBs (Figure 2A). Six DUBs
(Cezanne,Cezanne2–Lys11;OTUD4,OTUB1–Lys48;OTUD1–
Lys63; OTULIN – Met1) cleaved only one diUb substrate
(group I), four DUBs (OTUD3 – Lys6 and Lys11; A20, VCPIP –
Lys11 and Lys48; phosphorylated OTUD5 – Lys48 and Lys63)
cleaved two substrates (group II), and four DUBs (OTUD2,
Figure 1. Human OTU DUBs and Reactivity of Analyzed Constructs
(A) Phylogenetic tree of human OTU domain DUBs. HIN1L (*) is a pseudogene, and FAM105A (**) is lacking active site residues.
(B) Domain composition in human OTU DUBs (updated from Komander et al. [2009]).
(C) Constructs analyzed in this study. Full-length proteins not used in this study are shown in gray.
(D) Puriﬁed OTU proteins according to (C) resolved on a Coomassie-stained 4%–12% SDS-PAGE gradient gel. M, marker. Asterisks (*) indicate puriﬁed
constructs.
(E) Reactivity of analyzed constructs against the suicide probe Ub propargylamide (Ub-PA, upper panel) and Cy5-labeled Ub-PA (lower panel). Asterisks (*)
indicate the modiﬁed form of the OTU DUB.
See also Figure S1.
Cell 154, 169–184, July 3, 2013 ª2013 The Authors 171OTUD6A, OTUB2, TRABID) cleaved three or more chains prefer-
entially (groupIII)(Figures 2Aand 2B).ALG13,unphosphorylated
OTUD5, and OTUD6B were inactive in this assay (group IV)
despite being modiﬁed by Ub suicide probes (Figures 1E, S1A,
and S1B).
Increasing the concentration of DUB in the assay or using
longer incubation times led to the hydrolysis of linkages other
than the preferred linkage types (Figure S2). With the exception
of OTULIN, no tested DUB hydrolyzed Met1 linkages even at a
higher enzyme concentration or later time points (Keusekotten
et al., 2013), suggesting that OTU DUBs are mostly isopepti-
dases. The OTU DUB cleavage proﬁles differed from USP
domain DUBs that cleave all types of diUb with similar activity
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Figure 2. Linkage Speciﬁcity of Human OTU DUBs
(A) Puriﬁed OTU DUBs (constructs according to Figure 1C) were incubated with diUb of all linkage types for the indicated times and resolved on silver-stained
SDS-PAGE gradient gels. Enzyme concentration is as indicated and differs for each DUB. See Figure S2 for additional experiments.
(B)OTUDUBlinkagespeciﬁcityagainstdiUbsubstratescanbegroupedtoenzymescleavingonelinkagetype(groupI),twolinkagetypes(groupII),threeormore
linkage types (group III), or inactive enzymes (group IV).
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Figure 3. Roles for UBDs in OTU Speciﬁcity
(A) Surface representation of an OTU domain (blue) bound to a distal Ub molecule (yellow) with its C terminus reaching to the active site. The proximal Ub in the
dimer needs to bind such that only the preferred linkage point(s) (indicated in red on Ub surface) are presented to the active site.
(B) DUB assays performed as in Figure 2A with OTUD1 aa 287–481 (OTU+UIM, top) and 287–437 (OTU, bottom). The construct lacking the UIM domain is
nonspeciﬁc and less active (14.53 higher enzyme concentration used in gel below).
(C) Speciﬁcity analysis of different OTUD2 constructs. Top, OTUD2 lacking the UBX-like domain. Second from top, OTUD2 lacking the ZnF domain. Third from
top, OTUD2 isolated OTU domain. Bottom, OTUD2 with a mutation in the ZnF domain. The ZnF affects the ability of OTUD2 to cleave Lys27-, Lys29-, and Lys33-
linked diUb. See Figure S3 for additional experiments.
(D) Speciﬁcity assays of OTUD3 for constructs including the OTU and UBA domains (top) and the catalytic domain alone (bottom). The UBA domain has no
inﬂuence on diUb hydrolysis.
(E) Mechanism 1, positioning and orientation of the proximal Ub is achieved by its binding to a UBD present in the OTU enzyme.
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their linkage preference throughout evolution. S. cerevisiae
encode only two OTU DUBs, yOtu1 and yOtu2. yOtu1 and
D. melanogaster (dm) Otu1 are orthologs of human OTUD2
(38% and 53% identical in OTU domain, respectively), and
OTUD2 and yOtu1 both bind cdc48/p97 and are involved in
endoplasmic-reticulum-associated protein degradation (Ernst
et al., 2009; Rumpf and Jentsch, 2006). OTUD2 and yOtu1
preferred the same atypical linkages (Figures 2A and S2D),
whereas dmOtu1 also cleaved Lys6 linkages, indicating that
the linkage proﬁles of OTU enzymes are not necessarily identical
in different species (Figure S2E).
Altogether, this revealed that the OTU family had evolved
enzymes that recognize and hydrolyze speciﬁc Ub chain types.
Mechanisms of Linkage Speciﬁcity
Distinct Ub linkage speciﬁcity in members from a single DUB
family was unexpected and required a mechanistic explanation.
During the hydrolysis of diUb, both Ub moieties interact with the
DUB’s catalytic domain (Figure 3A). The distal Ub moiety binds
to the enzymatic S1 site and positions its C-terminal tail in the
catalytic site. This distal Ub is identical in each diUb molecule
anddoesnotexplainlinkagespeciﬁcity. Incontrast, theproximal
Ub moiety that binds to the enzymatic S1’ site contributes the
Lys to the isopeptide bond. Hence, mechanisms to position
and orient the proximal Ub moiety are the key to understand link-
age speciﬁcity in DUBs.
We selected three members of the OTUD family for additional
investigation: the unstudied Lys63-speciﬁc OTUD1, the cdc48/
p97 interactor OTUD2 that cleaves atypical linkages (Lys11,
Lys27, Lys29, and Lys33), and OTUD3, another unstudied DUB
with activity against Lys6- and Lys11-linked diUb (Figure 2A).
Roles for UBDs in Linkage Speciﬁcity
First, we tested whether UBDs in OTUDs contribute to posi-
tioning the proximal Ub toward the catalytic center. OTUD1
contains a C-terminal Ub-interacting motif (UIM, aa 457–476),
OTUD2 contains an UBX-like domain (aa 46–128) and a C-termi-
nal zinc ﬁnger (ZnF, aa 318–342), and OTUD3 contains a C-ter-
minal Ub-associated domain (UBA, aa 230–270). We compared
the activity and linkage speciﬁcity for truncated OTUD enzymes
(Figure 3).
The removal of the OTUD1 UIM had dramatic effects on activ-
ity and linkage speciﬁcity. Full-length OTUD1 or a construct
comprising OTU and UIM were highly active and Lys63 speciﬁc
(Figures 2A and 3B). The removal of the UIM in the OTU-only
construct rendered the protein less active (assay performed at
a14.53higherenzymeconcentration)and,importantly,nonspe-
ciﬁc (Figure 3B).Hence, in OTUD1, theUIM greatly increasedthe
speciﬁcity and efﬁciency of the enzyme toward Lys63 linkages.
This is similar to TRABID, where an N-terminal ankyrin-repeat
Ub-binding domain is required for Lys29 and Lys33 linkage
speciﬁcity (Licchesi et al., 2012).
Full-length OTUD2 cleaved Lys11-, Lys27-, Lys29-, and
Lys33-linked diUb (Figure 2A). Removal of the N-terminal UBX-
like domain did not affect OTUD2 speciﬁcity, but deletion of
the C-terminal ZnF domain or point mutations in zinc-binding
residues signiﬁcantly reduced activity toward Lys27-, Lys29-,
and Lys33-linked diUb without affecting Lys11 activity (Fig-
ure3C).ThesamewasobservedindmOtu1(FigureS3A).Hence,
the ZnF domain in OTUD2 enabled a Lys11-speciﬁc catalytic
core domain to cleave three additional linkage types. This sug-
gested that the OTUD2 ZnF is a UBD; however, we were unable
to detect an interaction with monoUb in nuclear magnetic reso-
nance (NMR) chemical shift perturbation experiments (Figures
S3B–S3E). UBDs do not always inﬂuence linkage speciﬁcity, at
least for diUb substrates, as shown for OTUD3, where the
removal of the UBA domain did not change its ability to cleave
Lys6- and Lys11-linked diUb (Figure 3D).
Hence, additional domains can both restrict and broaden the
linkage speciﬁcity proﬁle of OTU DUBs and fulﬁll important roles
in regulating OTU activity and linkage speciﬁcity (Figure 3E).
Notably,8ofthe16humanOTUDUBscontain UBDs(Figure1B),
suggesting that this could be a widely used mechanism. More-
over, UBDs in DUBs of other families (USPs and Josephins)
could have similar roles.
Sequence Speciﬁcity in OTU Domain DUBs
Isolated catalytic OTU domains showed distinct linkage speci-
ﬁcity against diUb substrates (Figures 3B–3D), and, next, we
investigatedwhethertheentireproximalUboronlythesequence
surrounding the ubiquitinated Lys was important for linkage
speciﬁcity. For this, ﬂuorescent ubiquitinated 14-mer peptides
derived from Ub (Figure 4A) (Geurink et al., 2012), as well as a
minimal ﬂuorescent Lys-Gly (KG) peptide, were used in ﬂuores-
cence anisotropy assays at ﬁxed substrate and increasing OTU
DUB concentrations (Figures 4 and S4).
InthemajorityofOTUDUBstested,thepeptideprobesdidnot
reﬂect the linkage speciﬁcity seen with diUb. OTUD1, OTUD3,
OTUB1, and Cezanne2 hydrolyzed most or all peptide
Figure 4. Linkage Speciﬁcity Determinants in the Proximal Ub
(A) Schematic representation (left) and sequence of generated ﬂuorescent ubiquitinated Ub peptides. The red K indicates the ubiquitination site in the peptide.
TAMRA refers to the ﬂuorescent group appended to the N terminus of the peptide.
(B–E) OTUD1 (B), OTUD3 (C), and OTUD2 (D and E) used at the different concentrations (indicated to the right) cleaved the indicated peptides over time. OTUD1
(B)andOTUD3(C)(aswellasOTUB1andCezanne2,seeFigureS4)hydrolyzedmostoforallthepeptidessimilarly,indicatingalackofsequencepreferenceanda
requirement for other regions in the proximal Ub to recover speciﬁcity. OTUD2 hydrolyzed all peptides if used at high enzyme concentrations (D) yet showed the
highest activity against the K6 and K11 peptide that were already hydrolyzed at the start of the measurement. Dilution of OTUD2 to picomolar concentrations (E)
revealed that the enzyme was sequence speciﬁc for a ubiquitinated peptide based on the Ub Lys11 context.
(F) Alanine scanning mutagenesis of the K11 peptide and assay with OTUD2 at 1 nM concentration as performed in (E). The y axis scale is the same in all graphs
except F4A. Residues affecting OTUD2-mediated hydrolysis are indicated in red in the sequence alignment (right). Leu15, not present in the K6 peptide, explains
the difference in sequence speciﬁcity between these similar peptides. Mutation of Lys6 to Ala resulted in an insoluble peptide, and Gly10 was not mutated. See
also Figure S4.
(G) Mechanism 2, OTUD2 is able to read the sequence context of the ubiquitination site, bind, and cleave in a sequence-speciﬁc fashion.
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176 Cell 154, 169–184, July 3, 2013 ª2013 The Authorssubstrates (Figures 4B, 4C, S4A, and S4B), albeit with reduced
activity for some combinations (e.g., OTUD1 against K33 pep-
tide, Figure 4B). This suggested that the recognition of the entire
proximal Ub fold is required for the linkage speciﬁcity of these
DUBs, which was consistent with the involvement of, for
example, UBDs (Figure 3).
In contrast, and to our surprise, OTUD2 displayed a marked
speciﬁcity for the peptide that was derived from the Lys11
sequence of Ub (K11 peptide, Figures 4D and 4E). OTUD2
hydrolyzed all peptide substrates at a high enzyme concentra-
tion but had already completely hydrolyzed the K11 peptide at
the start of the measurement (Figure 4D). Dilution of OTUD2 to
picomolar concentrations recovered complete speciﬁcity of the
DUB against the K11 peptide, and even the similar K6 peptide
was not hydrolyzed signiﬁcantly at low enzyme concentrations
(Figure 4E). To further understand this, we mutated each amino
acid of the ubiquitinated K11 peptide to Ala (Figure S4C). The
K6A peptide was insoluble, and Gly10 was not mutated. Exper-
iments performed at an OTUD2 concentration that cleaved
the K11 peptide revealed that Ala substitutions of Phe4, Val5,
Thr7, Leu8, Thr12, Ile13, and Leu15 signiﬁcantly reduced the
hydrolysis activity of the peptide (Figures 4F and S4D). Several
of these residues are solvent exposed in Ub, suggesting that
OTUD2 binds to these residues of the proximal Ub. However,
Ile13 and Leu15 are not exposed in folded Ub and, hence, are
unlikely to play a role in diUb recognition.
Nonetheless, this revealed another mechanism of OTU DUB
linkage speciﬁcity whereby OTUD2 selected the sequence
context of a ubiquitinated substrate, in this case recognizing
the Ub sequence surrounding Lys11 (Figure 4G).
Structural Studies on OTUD Family DUBs
To understand the speciﬁcity of OTUD domains at the molecular
level,wedeterminedhigh-resolutioncrystalstructuresofOTUD1
(aa 287–437, 2.1 A ˚ , Figures 5A and S5A), OTUD2 (aa 132–314,
1.5 A ˚ , Figures 5B and S5B), and OTUD3 (aa 52–209, 1.55 A ˚ , Fig-
ures 5C and S5C) (Table S1). The catalytic domains are structur-
ally similar to each other and to OTUD5 (Huang et al., 2012) and
S. cerevisiae Otu1 (yOtu1) (Messick et al., 2008), root-mean-
square deviations (rmsds) being from 0.6–1.0 A ˚ (Figure S5D).
Catalytic triads are in competent conformations, as observed
for pOTUD5 in complex with a Ub suicide probe (Huang et al.,
2012)( Figures S5D and S5E).
Furthermore, we determined the structure of OTUD2 bound to
the ubiquitinated K11 peptide (Figure 5D), representing the ﬁrst
structure of an OTU with an isopeptide bond spanning the active
site. Clear electron density for the isopeptide bond (Figure S5F)
and for four residues upstream and two residues downstream of
the ubiquitinated Lys revealed how the scissile bond reaches
across the active site. Unfortunately, the close packing of a
symmetry-related molecule (Figure S5G) most likely affects the
position of the peptide, and residues that affect K11 peptide
hydrolysis (Phe4, Val5, and Leu15) (Figures 4F and S4D) are
disorderedinthestructure.Thepeptidedoesnotformsigniﬁcant
contactswith the protein, which wouldhave beenexpected from
the peptide assay, suggesting that crystal lattice formation
affects peptide binding.
The Ub in the OTUD2 K11 peptide structure is located at a
similar position in the S1 site of the enzyme in comparison
to structures of OTUDs with Ub-based suicide inhibitors (Huang
et al., 2012; Messick et al., 2008)( Figures 5D and S5E). OTUD5,
but not yOtu1, requires activation by phosphorylation in the OTU
domain, which leads to the formation of the S1 Ub-binding site
(Huang et al., 2012)( Figure S5E). In OTUD1, OTUD2, and
OTUD3, the corresponding secondary structure elements are
present with or without Ub bound (Figure S5D), and there are
no large-scale conformational changes in OTUD2 upon Ub
binding (Figures 5B and 5D).
Conserved and Distinct OTU Domain S1’ Ub-Binding
Sites
The K11 peptide structure revealed how the isopeptide bond is
bound by OTU domains and how the proximal Ub is contacted
to form an S1’ substrate-binding site on OTUD DUBs. The Lys
side chain approaches the catalytic center across the loop pre-
ceding the catalytic Cys, termed the Cys loop (Figures 5H, 5I,
and S5H). The neighboring His loop connects the catalytic
His with a conserved upstream aromatic residue that forms
interactions with the C terminus of the distal Ub. A third loop,
the variable loop (V loop), located opposite to the His loop
Figure 5. Structural Studies on OTUD1, OTUD2, and OTUD3 Reveal a Conserved S1’ Site
(A–C) Crystal structures of the OTU domains of OTUD1 (A), OTUD2 (B), and OTUD3 (C). A cartoon representation in identical orientation is shown. The
S1 Ub-binding site, N and C termini, and N- or C-terminal a helix are labeled.
(D) Structure of inactive OTUD2 catalytic domain (C160A) in complex with the ubiquitinated K11 peptide (orange, see Figure 4) bound across the active site of the
enzyme (boxed) shown as in (B). The inset shows a stick model of the ubiquitinated peptide.
(E–G) Surface residues of OTUD1 (E), OTUD2 (F), and OTUD3 (G) are colored according to conservation of the protein throughout evolution (on the basis of the
alignments in Data S1).
(H)TopviewoftheputativeS1’siteinOTUD2.Thepeptidestructurein(D)revealshowtheisopeptideisboundacrosstheactivesiteofanOTUDUB.Cys,His,and
V loops as well as the C-terminal helix are indicated.
(I) Putative S1’ site in the structure of OTUD2 bound to the ubiquitinated K11 peptide. An arrow indicates the scissile bond.
(J) The same view as in (I) for the OTUB1 structure with two Ub moieties bound in S1 and S1’ sites (Wiener et al., 2012). The proximal Ub contacts the Cys and His
loops and also a dedicated S1’ binding site in a protruding N-terminal helix unique to OTUB1.
(K) Superposition of (I) and (J) showing the compatibility of S1’ binding sites.
(L)SequenceofCys,His,andVloopsinthehumanOTUDenzymes,yOtu1,anddmOtu1.Residues inredare‘‘anchor’’pointsofconservedstructuralresidues.An
asterisk (*) indicates catalytic Cys or His.
(M) A His loop mutation in OTUD3, R
178YGE to LSNG, creates a less active OTUD3 variant in which Lys11-diUb activity is more strongly affected than Lys6-diUb
activity (see also Figure S5K). Note the differences in enzyme concentration used in the assays.
(N) Mechanism 3, a conserved S1’ Ub-binding site on OTU DUBs positions the proximal Ub toward the catalytic center.
See also Figure S5.
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N-terminal helix in the OTUD1 and OTUD3 catalytic domain
and the structurally equivalent C-terminal helix of the OTUD2
catalytic domain form the putative S1’ site that binds the
proximal Ub (Figures 5H, 5I, and S5H). In recent complex
structures of OTUB1 with Ub bound in the S1’ site of the DUB
(Juang et al., 2012; Wiener et al., 2012) and of OTULIN bound
to Met1-linked diUb (Keusekotten et al., 2013), additional
N-terminal helices form extensive S1’ sites (Figures 5J, 5K,
S5I, and S5J). These are not present in minimal OTUD domains
(Figures 5I and S5H).
When the sequence conservation of OTUD orthologs from
species annotated in the Ensembl project (www.ensembl.org;
Data S1) is mapped onto the surface of OTUD1, OTUD2, and
OTUD3, the putative S1’ site comprising Cys and His loops
emerged as regions of highest surface conservation greater
than the S1 Ub-binding site (Figures 5E–5G). Importantly, the
amino acid sequence in the loops varies signiﬁcantly between
OTUD family members, in particular in the His and V loops (Fig-
ure 5L), indicating changes that may account for the observed
differences in linkage speciﬁcity.
We wondered whether mutations in the His and Cys loops
would change the cleavage proﬁle of OTUD DUBs. Substitution
of the His loop of OTUD3 by the corresponding sequence in
OTUD1 (mutating R
178YGE to LSNG) rendered the protein signif-
icantly less active in comparison to the wild-type (WT) enzyme
and affected its ability to target Lys11-linked, but not Lys6-
linked, diUb, even at very high concentrations (Figures 5M and
S5K).Hence,weengineeredanOTUdomainwithauniquespec-
iﬁcity proﬁle against diUb.
Altogether, the structural and mutagenesis data revealed
distinct S1’ Ub-binding sites on OTUD family enzymes that
contribute to their ability to target selected Ub linkages (Fig-
ure 5N). However, complex structures with diUb bound across
the active site are required to fully understand OTUD speciﬁcity
and to rationally design enzymes with new properties.
An S2 Site in OTUD2 Enables Speciﬁcity for Longer
Lys11-Linked Chains
Our attempts to generate substrate-bound OTUD structures
revealed an additional mechanism of speciﬁcity for OTUD2. In
a structure of inactive OTUD2 C160A in complex with Lys11-
linked diUb, the diUb molecule did not bind across the active
site but occupied S1 and a previously unidentiﬁed S2 site on
OTUD2 (Figure 6A). The S2 site is formed by two exposed hydro-
phobic residues (Ile292 and Val295) on the C-terminal OTUD2
a helix that bind the hydrophobic Ile44 patch of Ub (Figure 6B).
Theorientation ofUbboundtotheS2sitemostlikelyallowspref-
erential binding of Lys11-polyUb, given that the S2 Ub points
with its C terminus toward Lys11 of the S1 Ub (Figure 6A). Inter-
estingly, in the structure of OTUD2 C160A bound to the ubiquiti-
nated K11 peptide (Figure 5D), a second Ub in the asymmetric
unit occupied the S2 site in an identical manner (Figure 6C).
The S2 site in OTUD2 is conserved in higher eukaryotes but
not in yOtu1 and dmOtu1 (Figure 6B and Data S1).
We tested whether the S2 site was functionally relevant in iso-
lated catalytic domains of OTUD2 variants and mutated Ile292
and Val295 to Gln (referred to as OTUD2 MutS2), which did not
affect reactivity or diUb speciﬁcity (Figures S6A and S6B).
Next, we compared the activity of the OTU domains of OTUD2,
OTUD2 MutS2, and dmOtu1 toward Lys11-linked chains. All
proteins hydrolyzed Lys11-diUb similarly, but Lys11-linked tri-
and tetra-Ub were more rapidly cleaved to di- and mono-Ub
by WT OTUD2, whereas OTUD2 MutS2 or dmOtu1 did not
show enhanced activity for longer Lys11-linked chains (Figures
6D and S6C). The accumulation of Lys11-linked diUb indicated
that this product might be stabilized by binding the S1 and S2
sites on OTUD2, as was observed in the complex structures,
although OTUD2 MutS2 did not show enhanced diUb cleavage.
The S2 site speciﬁcally enhanced the cleavage of Lys11-linked
polyUb, given that Lys6-, Lys48-, or Lys63-linked triUb were
less well hydrolyzed by WT OTUD2 in comparison to MutS2 or
were not hydrolyzed at all (Figures 6E and S6D). OTUD1 does
not provide a structurally equivalent hydrophobic S2 site on
its a1 helix and is not enhanced in cleaving longer chains
(Figure S6E).
Hence the presence of an S2 site on the OTUD2 catalytic
domainallowsittospeciﬁcallytargetlongerLys11-linkedchains,
revealinganadditionalmechanismofOTUspeciﬁcity(Figure6F).
Linkage-Speciﬁc OTU DUBs Enable the
Characterization of polyUb Chains
Biochemical tools that allow the identiﬁcation of the Ub chain
typeonasubstrate arelimited.Massspectrometry,linkage-spe-
ciﬁc antibodies, Ub chain sensors, and Ub mutants have been
used to determine Ub chain type and topology, but all these
methodshavelimitations(KulathuandKomander,2012;William-
son et al., 2013).
We tested whether linkage-speciﬁc OTU DUBs could be used
in analogy to DNA restriction enzymes to hydrolyze speciﬁc link-
ages in complex samples to reveal the linkage type(s) present in
a ubiquitinated substrate. In combination, OTU DUBs can be
used to examine most linkage types (Figures 2 and 7A).
Using linkage-speciﬁc assembly systems, we generated
Lys63-, Lys48-, Lys11- and Met1-polyubiquitinated model
substrates in vitro, (see Experimental Procedures), which were
treated with a panel of DUBs (Figures 7A–7G and S6F–S6H).
Under these conditions, the nonspeciﬁc enzyme USP21 (Ye
et al., 2011) hydrolyzed most or all ubiquitin linkages, whereas
the nonspeciﬁc vOTU DUB (Akutsu et al., 2011) efﬁciently
removed all isopeptide-linked polyUb.
Linkage-speciﬁc OTU DUBs were used at a low concentration
in order to maximize DUB speciﬁcity, and they were also used at
a3 3–103 higher concentration in order to drive preferred reac-
tions to completion (Figure 7B). DUB-treated samples were
resolved on SDS-PAGE gradient gels and analyzed by silver
staining and/or western blotting. Three parameters indicated
that DUBs affected the substrate: (1) the reduction of high-
molecular-weight (HMW) polyUb, (2) the emergence of monoUb,
and (3) the appearance of free chains released from HMW
species.
The OTU DUBs cleaved polyUb substrates according to their
speciﬁcity proﬁles. OTUD1 reduced Lys63-polyUb to monoUb
(Figures 7C, 7D, S6F, and S6G), and OTUB1 generated monoUb
from E6AP-assembled Lys48-polyUb (Figures 7E and S6H).
OTUD3, Cezanne, and OTUD2 hydrolyzed UBE2S-assembled
178 Cell 154, 169–184, July 3, 2013 ª2013 The AuthorsLys11-linked chains, and diUb accumulated in OTUD2-treated
samples (Figure 7F). Only OTULIN hydrolyzed HOIP-assembled
Met1-linked chains (Figure 7G).
Interestingly, in some cases, OTUD DUBs released intact
polyUb chains from substrates (Figures 7C–7E and S6F–S6H).
This could be due to the presence of chain types other than
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Figure 6. Complex Structures of OTUD2 Reveal an S2 Ub-Binding Site
(A) Structure of the inactive OTUD2 OTU domain (C160A) bound to Lys11-linked diUb in the S1 and S2 site of the enzyme. The orientation of the Ub molecules is
compatible with Lys11 linkage, although the linker sequence is not resolved in the electron density maps (indicated by arrows).
(B) Close-up image of the hydrophobic S2 site on the a6 helix formed by Ile292 and Val295, which interact with the Ile44 patch of Ub. An alignment shows
conservation of this sequence in different species (see also Data S1).
(C) Structure of inactive OTUD2 incomplex with the ubiquitinated K11peptide as in Figure 5D. A second Ub for which the peptide is disordered is bound in the S2
site (see Figure S5G).
(D) DUB assays with Lys11-linked Ub chains. Assays comparing isolated catalytic domains of WT OTUD2 (aa 147–314) and S2 site mutant (MutS2, aa 147–314,
I292Q, V295Q) as well as dmOtu1 (aa 143–313) toward Lys11-diUb (top), Lys11-triUb (middle), and Lys11-tetraUb (bottom). Human OTUD2 hydrolyzed tri- and
tetra-Ub immediately, and this depended on the S2 site of the enzyme.
(E) Cleavage of differently linked triUb chains. In comparison to (D) and Figure 2A, a 4-fold lower enzyme concentration was used.
(F) Mechanism 4, an S2 Ub-binding site on OTU DUBs allows the DUB to target and speciﬁcally hydrolyze longer Ub chains.
See also Figures S6A–S6E.
































































































































































































































































Figure 7. Exploiting OTU DUBs in Ub Chain Restriction Analysis
(A) Schematic of the principle of Ub chain restriction analysis.
(B–I)Ubchainrestrictionanalysisagainsttheindicatedsubstrates.SDS-PAGEgradientgelsweresilver-stained(B–E,G,andH)orwesternblottedwithanti-Ub(F)
or anti-RIP1 (I). M, marker; Control, ubiquitinated protein without DUB treatment. Enzyme bands are highlighted in silver-stained gels (green boxes).
(B) Enzyme input reference gel.
(C) GST-TRAF6, UBE2N, and UEV1A generated free and attached Lys63-linked polyUb. See Figure S6F for an anti-Ub western blot of this gel.
(legend continued on next page)
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isopeptide linkage between substrate and Ub chain, or the hy-
drolysis of branched Ub polymers. Importantly, released intact
polyUb chains could still be used to identify chain types, given
that differently linked polyUb chains have distinct electro-
phoretic mobility. OTUD2 released chains from GST-tagged
NEDD4 and E6AP, which showed identical electrophoretic
mobility to free Lys48- or Lys63-linked polymers, respectively
(Figure 7H). A double band for triUb observed in a OTUD2-
treated UBE2S sample indicated small amounts of Lys63 link-
ages in the reaction, as reported previously (Bremm et al., 2010).
In the case of GST-E6AP, DUB treatment was inefﬁcient, and
HMW species remained, even at high concentration of DUBs
(Figure 7E). This is consistent with recent data showing that
longer Lys48 chains may be more resistant to DUB hydrolysis
(Schaefer and Morgan, 2011; Ye et al., 2012).
Altogether, our data showed that OTU DUBs maintained their
speciﬁcity when tested against polyubiquitinated substrates.
To test their action against endogenously ubiquitinated sub-
strates, we puriﬁed the TNF receptor signaling complex (TNF-
RSC) using FLAG-tagged TNFa. The TNF-RSC contains many
ubiquitinated proteins, including RIP1, which can be detected
by western blotting with an antibody against RIP1 (Figure 7I)
and was previously shown to be modiﬁed with at least four
different Ub chain types (Gerlach et al., 2011). When treated
with the DUB panel, OTUD1 substantially reduced HMW forms
of RIP1, suggesting the prevalence of Lys63 linkages on RIP1.
OTUD2 was also able to reduce the polyUb RIP1 signal, but, in
this experiment, it cannot be assessed whether OTUD2 also
released polyUb chains. In comparison, Cezanne, OTUB1, and
OTULIN treatment did not lead to a strong reduction of the
polyUb signal (Figure 7I), suggesting that Lys11-, Lys48-, and
Met1-linked chains only account for a small fraction of the total
linkages in RIP1.
Altogether, these experiments showed that OTU DUBs can be
usedto interrogate thetype and relativeabundance ofUb chains
on substrates. We believe that Ub chain restriction analysis will
be a useful tool in Ub chain research.
DISCUSSION
OTUs: A Remarkable DUB Family
Deubiquitinases are the subject of intense research, and many
are intimately linked to human disease. Here, we characterized
the second largest human family of DUB enzymes biochemically
and structurally to discover that individual OTU DUBs have
evolved distinct Ub linkage speciﬁcities. This ﬁnding is in
contrast to USP DUBs, which cleave most Ub chain types indis-
criminately (Faesen et al., 2011) and to JAMM family enzymes,
many of which are Lys63 speciﬁc (Cooper et al., 2009). This
insight immediately suggests that OTU DUBs may be less spe-
ciﬁc to the ubiquitinated protein per se and that their role is to
regulate the abundance of selected Ub chain types that may
arise under certain physiological conditions.
Four Mechanisms of Ub Linkage Speciﬁcity
We identify four distinct mechanisms of how OTU DUBs achieve
linkage speciﬁcity. Of these mechanisms, two rely on proper
positioning of the proximal Ub, which is achieved by either addi-
tional UBDs or an S1’ Ub-binding site on the OTU domain itself.
Future structural studies of DUB polyUb complexes may allow
DUB speciﬁcity engineering to generate enzymes with improved
speciﬁcity, which would be beneﬁcial for Ub chain restriction
analysis and deeper understanding Ub chain biology.
Furthermore, wefoundthatmostOTUDUBshydrolyzeubiqui-
tinated Ub-derived peptides nonspeciﬁcally, indicating that an
intactproximalUbisrequiredfortheirlinkagespeciﬁcities,which
is consistent with aforementioned mechanisms. Interestingly,
OTUD2 was highly selective for a ubiquitinated peptide derived
from the Lys11 context of Ub, and an Ala scan revealed the res-
idues involved in this speciﬁcity. Some of these residues (Ile13
and Leu15) are not exposed in Ub and do not explain the
observed chain speciﬁcity but indicate that hydrophobic
patches are most likely involved in proximal Ub recognition.
The identiﬁcation of a seemingly sequence-speciﬁc DUB fuels
an ongoing debate on sequence speciﬁcity in protein ubiquitina-
tion. Global proteomic studies indicate a lack of sequence pref-
erence in protein ubiquitination sites (Kim et al., 2011; Wagner
et al., 2011), and current models suggest that E3 ligases target
a ‘‘ubiquitination zone’’ on substrates to modify accessible Lys
residues within reach of the E3 ligase. However, the anaphase
promoting complex (APC/C) preferentially ubiquitinates an initia-
tion motif in its substrates (Williamson et al., 2011), suggesting
that ubiquitination may, in some cases, be sequence speciﬁc.
Our structural studies of Ub and diUb complexes for OTUD2
unexpectedly revealed another mechanism that targets OTUD2
to longer Ub chains. Both complex structures uncovered an S2
site on the OTU domain itself, and our functional studies indicate
that this site provides a mechanism for enhancing activity, and
therefore speciﬁcity, toward longer K11-linked Ub chains. It is
possible that the UBDs in other OTU DUBs (and in other DUB
families), may serve similar roles in targeting the enzymes to
polyUb-modiﬁed substrates. These four mechanisms, along
with the mechanism of substrate-assisted catalysis in OTULIN
(Keusekotten et al., 2013), provide a basis for understanding
linkage speciﬁcity in DUBs.
Physiological Questions Arising
Many members of the OTU family have remained relatively
unstudied. The best-studied OTU enzymes are the Ub-chain-
editing enzyme A20, an important negative regulator of NF-kB
signaling (Hymowitz and Wertz, 2010), and OTUB1, a protein
(D) Lys63-autoubiquitinated GST-tagged NEDD4 HECT domain with UBE2L3. See also Figure S6G.
(E) Lys48-autoubiquitinated GST-E6AP with UBE2L3. See also Figure S6H.
(F) Lys11-autoubiquitinated UBE2S containing contaminating Lys63 linkages (Bremm et al., 2010).
(G) Met1-linked polyUb generated by a minimal HOIP construct with UBE2L3.
(H) OTUD2 released polyUb chains from GST-E6AP and GST-NEDD4 compared to free Lys48- and Lys63-polyUb.
(I) Ub chain restriction analysis of polyubiquitinated RIP1 generated by FLAG-TNFa mediated puriﬁcation of TNF-RSC from human embryonic kidney 293T cells.
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Both enzymes prefer Lys48-linked polyUb, but it is not clear
whether this linkage speciﬁcity is relevant for their function. Cur-
rent models require A20 to hydrolyze Lys63 linkages (Hymowitz
and Wertz, 2010), whereas OTUB1 was shown to have noncata-
lytic functions by acting as a cellular buffer for charged E2 en-
zymes (Nakada et al., 2010). Particularly for A20, the low activity
fortheOTUdomainsuggeststhat,forexample,posttranslational
modiﬁcations or one of the Ub-binding A20-interacting proteins
(Hymowitz and Wertz, 2010) could modulate its activity and/or
speciﬁcity.
An interesting observation is the speciﬁcity observed for
OTUD2 and VCPIP. Both enzymes efﬁciently cleave Lys11-
linked chains and interact with p97 (Ernst et al., 2009; Wang
et al., 2004), suggesting that p97 may act on substrates contain-
ing atypical linkage types, although the role of DUBs in p97 func-
tion is not well understood (Tsai and Weissman, 2011). The
similar speciﬁcity of OTUD2 and OTUD6A, another unstudied
OTU DUB, may suggest functional similarities. An additional
enzyme worth studying is OTUD3, given that it is, so far, the
only DUB that cleaves Lys6-linked diUb with some degree
of speciﬁcity. Lys6-linked polyUb is an enigmatic chain type
for which cellular roles are currently unclear (Kulathu and
Komander, 2012). Understanding the relevant interactions of
OTU DUBs (Sowa et al., 2009) may indicate physiological func-
tions for unstudied atypical Ub chain types.
OTUs as Tools in Ub Chain Research
We are excited by the prospects of Ub chain restriction analysis
in which linkage-speciﬁc OTU DUBs are used in vitro to reveal
the identity of the Ub chain type(s) on proteins, and we have
recently reported that they are useful reagents to interrogate
chain architecture in heterotypic chains (Hospenthal et al.,
2013). However, there are several caveats. The amount of poly-
ubiquitinated substrate is often unclear, especially in western
blotting applications. Also, the length, complexity, and number
of Ub chains on in vitro generated polyubiquitinated proteins
are often unknown. Therefore, each application of restriction
analysis requires careful titration of each DUB to prevent off-
targetreactions.ThisisexaggeratedwhenDUBactivitydepends
on chain length (as seen for OTUD2). Furthermore, it is currently
unclear whether OTU DUBs can hydrolyze the ﬁrst Ub linkage
(between substrate and proximal Ub) and how OTU DUBs deal
with branched polyUb (in which one Ub is modiﬁed at two or
more Lys residues, generating a forked structure). OTUB1 and
OTUD3 hydrolyze heterotypic (mixed and branched) and homo-
typic chains equally well (Hospenthal et al., 2013; Nakasone
et al., 2013).
Although some OTU DUBs seem remarkably speciﬁc (OTUB1
does not hydrolyze Lys6 linkages, even at high concentration in
overnight reactions) (Hospenthal et al., 2013), the small OTUD
family enzymes will cleave any linkage type when used at high
concentrations or over long time courses. With a deeper under-
standing of OTU DUB mechanisms, speciﬁcity, and additional
structural insights, efforts to ‘‘design’’ speciﬁcity in OTU DUBs
may generate enzymes with improved speciﬁcity and activity.
The use of Ub chain restriction analysis is not limited to OTU
DUBs—other DUB families, in particular the Lys63-speciﬁc
JAMM enzymes, could be excellent additional tools for these
purposes.
In addition to Ub chain restriction analysis, there are several
other ways linkage-speciﬁc OTU DUBs could be exploited;
e.g., in mass-spectrometric applications to reveal proteins in
lysates harboring particular chains types or when inactivated
DUBs are used as linkage-speciﬁc UBDs to enrich certain link-
age types. Clearly, OTU family DUBs will continue to be valuable
tools in understanding the complex biology of protein ubiquitina-
tion events.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Puriﬁcation of OTU DUBs
cDNAs for OTU DUBs were obtained from the IMAGE consortium by ampliﬁ-
cation from human cDNA libraries or as a gift from kind colleagues. Constructs
according to Figure 1C were expressed in E. coli from pOPIN-K vectors and
puriﬁed by afﬁnity chromatography, anion exchange, and gel ﬁltration.
Modiﬁcation of OTU DUBs by Suicide Probes
Ub-PA was generated as described in Ekkebus et al. (2013) and Ub-, NEDD8-,
and ISG15-derived haloalkyl probes were generated according to Akutsu et al.
(2011) and Borodovsky et al. (2002). DUB reactivity assays were performed at
room temperature for 1 hr (Ub-PA), 3 hr (haloalkyl probes), or as indicated.
In Vitro DUB Assays
Qualitative in vitro DUB linkage speciﬁcity assays were performed as in
Licchesi et al. (2012).
Crystallization and Structure Determination
Crystallization screening was performed in a sitting drop setup with com-
mercial screens. Structures were determined by molecular replacement (see
Table S1).
Fluorescence Polarization DUB Assay
Ub-based ﬂuorescence polarization substrates were used as previously
described (Geurink et al., 2012).
Ub Chain Restriction Analysis
DUBs were diluted to 23 indicated concentrations, mixed with substrate, and
incubated for 15 min at 37C. Reactions were stopped by adding 43 lithium
dodecyl sulfate sample buffer, resolved on 4%–12% SDS-PAGE gradient
gels, and analyzed by silver staining and/or western blotting. Protocols for
the generation of model substrates are described in detail in the Extended
Experimental Procedures.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited with the Protein Data
Bank under the following accession numbers: OTUD1, 4BOP; OTUD2, 4BOQ;
OTUD3, 4BOU; OTUD2-Lys11-diUb, 4BOZ; and OTUD2 UbK11 peptide,
4BOS.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
ﬁgures, one data set, and one table and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2013.05.046.
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EXTENDED EXPERIMENTAL PROCEDURES
Cloning and Molecular Biology
Full-length OTUDUBs werecloned from IMAGE clones, cDNA libraries, or from plasmids thatwere kinds gifts fromC.Schlieker (Yale
University,OTUD2),B.Kessler(UniversityofOxford,OTUB1), M.Balakirev(CEA Grenoble,OTUB2), R.Marmorstein(WistarInstitute,
yOtu1), S. Todi (Wayne State University, dmOtu1), S. Urbe (University of Liverpool, VCPIP). DNA sequences to generate proteins
listed in Figure 1C were PCR ampliﬁed using KOD HotStart polymerase (Novagen) and cloned into pOPIN (Berrow et al., 2007)
vectors using the In-Fusion HD system (Clontech) according to the manufacturer protocol. Mutagenesis was performed using the
QuikChange protocol, but using KOD polymerase according to manufacturer’s protocol.
Protein Expression and Puriﬁcation from Bacteria
For bacterial production, protein was expressed from pOPIN-K vectors, which introduces a PreScission protease cleavable
N-terminal His6-GST tag. Protein was expressed in E. coli Rosetta2 pLacI cells that were grown to an OD600 of 0.8-1.0 at 37 C
and induced with 1 mM IPTG for 16-20 hr at 20 C. Large-scale protein expression was performed in 2-12 L LB or 2xTY medium
supplemented with the appropriate antibiotics.
Protein puriﬁcations were performed at 4 C. Cells were lysed by sonication in 50-100 ml lysis buffer (200 mM NaCl, 25 mM Tris
[pH8.5], 5 mM DTT, 1 EDTA free Complete protease inhibitor tablet, 0.1 mg/mL DNase, 1 mg/mL lysozyme), and cleared by centri-
fugation 35000 rpm for 45 min. The cleared lysate was incubated with 1.5-3 ml equilibrated Glutathione Sepharose 4B resin (GE
Healthcare) for 1 hr, and subsequently washed with 2 L buffer A (25 mM Tris [pH 8.5], 5 mM DTT) plus 500 mM NaCl, and 500 ml
buffer A plus 50 mM NaCl. The GST tag was cleaved on the resin with 50 mg GST-tagged PreScission protease overnight. Cleaved
protein was eluted with buffer A plus 50 mM NaCl to a ﬁnal volume of 50 mL, and subjected to anion exchange chromatography
(ResourceQ 1mL, GE Healthcare). OTU DUBs usually elute as a single peak in buffer A with a NaCl gradient from 50 to 500 mM.
Peak fractions were pooled and subjected to gel ﬁltration (Superdex75) in buffer A plus 200 mM NaCl. Proteins were concentrated
to 2-20 mg/mL using a VivaSpin 10 kDa MW cut-off concentrator and ﬂash-frozen in liquid nitrogen.
OTUD5 (aa 171-358) was catalytically inactive when produced in E.coli, as reported (Huang et al., 2012). Incubation of 500 mg
OTUD5 (10 mg/mL) with 150 U of casein kinase 2 (CK2) in 20 mM Tris (pH 7.5), 50 mM KCl, 10 mM MgCl2, 10 mM ATP for 4 hr at
30 C resulted in phosphorylation and activation of the enzyme. The reaction was stopped by addition of 20 mM EDTA (ﬁnal concen-
tration) and used for DUB assays.
Modiﬁcation of OTU DUBs by Suicide Probes
Generation of Ub-, NEDD8- and ISG15-derived chemical probes was performed according to published protocols (Akutsu et al.,
2011; Borodovsky et al., 2002). Puriﬁed Ub- and Ubl-thioesters were diluted with DUB dilution buffer (150 mM NaCl, 25 mM Tris
(pH 7.5), and 10 mM DTT) to a ﬁnal concentration of 2 mg/mL. 200 ml Ub-/Ubl-thioester was mixed with 40 mg 2-bromoethylamine
hydrochloride solved in 200 ml phosphate buffered saline (PBS [pH 4.8]). The reaction was initiated by adding 80 ml 2 M NaOH and
incubated for 15 min on ice. Subsequent dialysis against probe buffer (200 mM NaCl, 25 mM Tris [pH 7.5]) was performed using
Slide-A-Lyzer Dialysis Cassettes (Thermo Scientiﬁc).
Ub propargylamide (Ub-PA) and Cy5-labeled Ub-PA were generated according to (Ekkebus et al., 2013). Ub-PA probes were
dissolved in DMSO, diluted to 1.7 mg/mL in H2O and 1:1 mixed with 2x probe buffer.
For suicide probe assays, 8 ml of OTU DUB diluted to 0.4 mg/mL in DUB dilution buffer, was mixed with 20 ml Ub-, NEDD8- or
ISG15-derivedprobesat0.83mg/mL.Afterincubationatroomtemperatureforindicatedtimes,thereactionwasstoppedbyaddition
of 10 ml 4x LDS sample buffer (Invitrogen). 13 ml of each sample was resolved by SDS-PAGE prior to staining using Instant Blue
SafeStain (Expedeon). vOTU (Akutsu et al., 2011) was used as a positive control as it is readily modiﬁed with each probe (Figures
1 and S1).
In Vitro DUB Assays
Qualitative in vitro linkage speciﬁcity assays were performed as described in (Licchesi et al., 2012). In brief, a 2x reaction stock is
prepared containing 2 mg diUb, 100 mM NaCl, 100 mM Tris (pH 7.5), 10 mM DTT. To this is added 10 ml of 2x concentrated DUB
in DUB dilution buffer. DiUb concentrations are re-adjusted frequently. Pilot experiments identiﬁed the required DUB concentration
that resulted in robust cleavage of the preferred chain type.
TheassayisstartedbymixingDUBanddiUbsolutions,and5mlaliquotsaretakenatindicatedtimepoints.Thereactionisresolved
on 4%–12% SDS-PAGE gradient gels run in MES buffer (Invitrogen) and stained by silver staining using the SilverStain Plus kit
(BioRad).
NMR Analysis of the OTUD2 ZnF Domain
Expression of
13C,
15N-labeled OTUD2 ZnF constructs was performed in 2 L M9 minus medium supplemented with 2 mM MgSO4,
50 mM ZnCl2,1 0mM CaCl2 (all ﬁnal concentrations), 10 ml E. coli trace elements, 4 g
13C-glucose, 2 g
15N-labeled NH4Cl and anti-
biotics. Cultures were grown at 37 C to an O.D.600 of 0.8-1.0, and cooled down to 20 C prior to induction with 1 mM IPTG. 200 mM
ZnSO4 was added at the time of induction. GST-tagged protein was puriﬁed as described above, and stored in NMR buffer (18 mM
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NMR buffer. Samples were prepared in 500 ml NMR buffer, supplemented with 35 mlD 2O and transferred to a NMR tube.
NMR acquisition was carried out at 298 K on a Bruker Avance 600 MHz spectrometer equipped with a TCI triple resonance cryo-
probe. In order to assign the ZnF domain of OTUD2, standard triple resonance experiments (CBCA(CO)NH and HNCACB) were
acquired. For chemical shift perturbation experiments, HSQC (Heteronuclear Single Quantum Coherence) spectra were recorded
for 50 mM
13C,
15N-labeled OTUD2 ZnF alone and in the presence of 1 mM unlabeled Ub. The reverse experiment was performed
with 80 mM
13C,
15N-labeled Ub alone and with 400 mM unlabeled OTUD2 ZnF.
Data processing and analysis were carried out in TopSpin (Bruker BioSpin) and Sparky (Goddard TD & Kneller DG, University of
California, San Francisco), respectively. The full backbone of OTUD2 ZnF was assigned using MARS (Jung and Zweckstetter, 2004).
Crystallization of OTU DUBs
Crystallization screening was performed using nano-liter robotics (typical volume 100+100 nL) in a sitting drop setup, using up to
1800 conditions from commercial screens per protein. Most crystal hits were reproduced in hanging-drop setup. OTUD1 crystals
grew at 20 C from Morpheus screen (Gorrec, 2009) condition C7, containing 10% (v/v) PEG 4000, 0.1 M Buffer 2, 0.09 M NPS,
20% (v/v) glycerol. The small crystals were vitriﬁed in liquid nitrogen. OTUD2 crystals grew at 20 C from 0.8 M sodium phosphate
monobasic monohydrate, 0.1 M Tris [pH 7.5]. For synchrotron data collection, crystals were soaked in mother liquor containing
30% glycerol, and vitriﬁed in liquid nitrogen. OTUD3 crystals grew from 10% (v/v) PEG 400, 0.1 M KCl, 0.01 M MgCl, 50 mM
MES(pH6.0).Crystalswerecryo-cooled afterbrief soakinginmotherliquorcontaining15%(v/v)glycerol.OTUD2C160Aincomplex
with Lys11-linked diUb grewfrom0.15Mpotassiumthiocyanate, 18%(w/v) PEG5000MME, 0.1Msodiumacetate(pH 5.5).Crystals
were soaked inmother liquorcontaining 30%glycerol prior todata collection. OTUD2C160A incomplex with aubiquitinated peptide
weregrownin21%(v/v)PEG3350,100mMNaOAc(pH5.6),200mMMg(NO3)2.Crystalsweretransferredintoparatone-N-oilpriorto
vitriﬁcation in liquid nitrogen.
Data Collection, Phasing, and Reﬁnement
DiffractiondatawerecollectedattheESRF(Grenoble,FR),beamlinesID23-1andID29,andattheDiamondLightSource,beamlines
I-03 and I-04. OTUD1 crystals were in space group I4 with two molecules in the asymmetric unit (mol/AU) and diffracted to 2.1 A ˚ res-
olution. OTUD2 apo crystals were in space group P3121 with one mol/AU and diffracted to 1.5 A ˚ resolution. OTUD3 crystals were in
spacegroupP3212anddiffractedto1.55A ˚ resolutionwith1mol/AU.OTUD2C160AcrystalsincomplexwithLys11-linkeddiUbwere
in space group C2, diffracted to 3.0 A ˚ and contained 2 OTUD2 and 3 Ub molecules in the AU. OTUD2 crystals in complex with
ubiquitinatedK11peptidewereinspacegroupP6with2OTUD2and2UbmoleculesintheAUanddiffractedto2.35A ˚ (seeTableS1).
Phases were obtained by molecular replacement in Phaser (McCoy et al., 2007), using reﬁned structures as listed in Table S1 as
search models. Balbes (Long et al., 2008) identiﬁed a fragment of OTUD5 lacking the N-terminal helix as the best search model for
OTUD3, and this was used in molecular replacement in Phaser. For high resolution structures (OTUD1, OTUD2, OTUD3), initial
models were automatically built by WarpNTrace (Langer et al., 2008). Structures were built in Coot (Emsley and Cowtan, 2004)
and reﬁned in PHENIX (Adams et al., 2002) or Refmac (Murshudov et al., 2011), including simulated annealing and TLS B-factor
reﬁnement where appropriate. In the case of OTUD3, B-factors were reﬁned with anisotropic restraints. Final statistics for all struc-
tures can be found in Table S1.
Fluorescence Polarization DUB Assay
The Ub-based FP substrates and peptides were used as described in (Faesen et al., 2011) and (Geurink et al., 2012). FP assays were
performed using a Pherastar plate reader (BMG Labtech) equipped with a 550 nm excitation ﬁlter and two 590 nm emission ﬁlters.
Fluorescence intensities weremeasuredintheS(parallel) andP(perpendicular) direction.FPvaluesaregiveninmP(millipolarization)
and calculated using the Equation 1:
PolarizationðmPÞ=
S  ð G$PÞ
S+ðG$PÞ
31000 (Equation 1)
Theconfocal opticswere adjusted with theaverage P andSvalues for TAMRA-KG and thegrating factor (G)wasdetermined using















The assays were performed in ‘‘non binding surface ﬂat bottom low ﬂange’’ black 384-well plates (Corning) at room temperature in
a buffer containing 20 mM TrisHCl, pH 7.5, 5 mM DTT, 100 mM NaCl, 1 mg/mL 3-[(3-cholamidopropyl) dimethylammonio] propane-
sulfonic acid (CHAPS) and 0.5 mg/mL bovine gamma globulin (BGG). Each well had a volume of 20 mL. Buffer and enzyme (OTUD1,
OTUD2, OTUD3, OTUB1, Cezanne2) were predispensed (10 mL/well) and the reaction was started by the addition of substrate
S2 Cell 154, 169–184, July 3, 2013 ª2013 The Authors(10 mL/well, 5 mM ﬁnal concentration (0.5 mM for OTUD1)). The plate was centrifuged (1 min at 1,500 rpm) prior to the measurement.
Kinetic data were collected in intervals of 30 s. The obtained data were ﬁtted according to a ‘one phase exponential decay’ using
Prism 5.01 (GraphPad Software).
Generation of Model Substrates for Ub Chain Restriction Analysis
Lys63-polyUb was assembled using TRAF6/UBE2N/UBE2V1 (Deng et al., 2000) and Lys11-polyUb using UBE2S according to
(Bremm et al., 2010). GST-tagged E6AP and NEDD4 (kind gift from Thomas Mund, MRC LMB) were autoubiquitinated using
100 nM wheat E1, 2.3 mM UBE2L3, 10 mM E3, 50 mMU b( Kim and Huibregtse, 2009). Met1-linked polyUb was assembled using
5 mM HOIP 699-1072, 100 nM wheat E1, 6 mM UBE2L3, 0.25 mg/mL Ub (Smit et al., 2012). All substrates except HOIP were puriﬁed
on a AKTA Micro system to remove short free chains and monoUb.
TNF Receptor Puriﬁcation
TNFRSC was puriﬁed from the indicated cell lines after stimulation with 100 ng/mL Flag-TNFa (Human TNFa, from Alexis) for 10 min.
Ice-cold PBS was added to the plate to stop stimulation. Following lysis, TNFRSC was puriﬁed by incubation with Flag M2 agarose
beads (Sigma). TNFR was puriﬁed from the unstimulated sample by adding 1 mg of TNFa during lysis. The puriﬁed TNFRSC was
analyzed by western blotting for RIP1. Ub chain restriction analysis was performed on beads.
Ub Chain Restriction Analysis
DUBs were diluted to 2x indicated concentrations in 150 mM NaCl, 25 mM Tris (pH 7.5), and 10 mM DTT and activated at 23 C for
10 min. Subsequently, 5 ml of diluted enzyme were mixed with 5 ml substrate, incubated for 15 min at 37 C, and the reaction stopped
by adding 10 ml 4x LDS sample buffer (Invitrogen). 1-10 ml of the reaction was resolved on 4%–12% SDS-PAGE gradient gels run in
MES buffer, and visualized by silver staining (SilverStain Plus Kit, BioRad) or by western analysis using polyclonal anti-Ub antibody
(Millipore).
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Figure S1. Reactivity of Human OTU DUBs with Probes Derived from Ub and Ub-like Modiﬁers, Related to Figure 1
(A) OTU DUBs shown alone and after incubation with the suicide probe Ub-propargylamide (Ub-PA, 1 hr reactions). Asterisks (*) indicate modiﬁed forms of DUB.
(B) Reactivity of ALG13 and A20, which did not react with Ub-PA (Figures 1E and S1A 1 hr reactions) against Ub-PA and Ub bromoethylamine (C2Br).
(C) Reactivity of OTU DUBs against ISG15-C2Br (3 hr reactions). Only vOTU is modiﬁed, indicated by an asterisk (*).
(D) Reactivity of OTU DUBs against NEDD8-C2Br (3 hr reactions). Asterisks (*) indicate NEDD8 modiﬁed enzymes.
(E) Fluorescence anisotropy assays of selected OTU domains (boxed in D) against ﬂuorescent ubiquitinated or neddylated KG peptides. The raw data are shown
at different enzyme concentrations.
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Figure S2. Additional DUB Assays for Selected OTU DUBs, Related to Figure 2
(A) OTUD1 constructs tested at 223 concentration (top) or at 103 concentration and longer time course (24 hr, bottom) compared to Figure 2A showing that
under these conditions, other linkages are hydrolyzed.
(B) OTUD2 DUB assay at long time points (24 hr).
(C) DUB assay of Cezanne at 103 higher concentration reveals that all isopeptide-linked diUb are hydrolyzed.
(D) Linkage speciﬁcity of S. cerevisiae Otu1 (yOtu1), aa 91–301 (Messick et al., 2008). yOTU1 has a similar linkage speciﬁcity proﬁle as its human counterpart
OTUD2.
(E)DUB assayofD.melanogasterOtu1(dmOtu1),aa 143–347,showsasimilarcleavagepatterncompared tohuman andyeastorthologs butadditionallycleaves
K6-linked diUb.
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Figure S3. Impact of the ZnF Domain on dmOtu1 Speciﬁcity and the Ability of the Human OTUD2 ZnF Domain to Bind monoUb, Related to
Figure 3
(A) Speciﬁcity analysis of different dmOtu1 constructs. Top, dmOtu1 lacking the UBX-like domain. Bottom, isolated catalytic OTU domain. As in the human
ortholog OTUD2, the ZnF domain affects the enzyme’s ability to cleave Lys27-, Lys29- and Lys33-linked diUb.
(B) Sequence of the analyzed human OTUD2 ZnF construct (aa 314–348).
(C) Fully assigned ZnF spectrum derived from 3D NMR experiments.
(D)UbbindingexperimentwithOTUD2ZnFconstruct.Shownareoverlaidspectra of50mMOTUD2ZnFalone(blue)andwithadditionof1mMunlabeledUb(red).
The boxed section is shown in close-up view below. The lack of chemical shift perturbations indicate no binding of the ZnF to monoUb.
(E) The reverse experiment from (C), using 80 mM labeled Ub and 400 mM unlabeled OTUD2 ZnF. Again, no Ub residue is perturbed, hence there is no binding
under these conditions.
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Figure S4. Additional Fluorescence Polarization Assays and Ala Scan of the K11 Peptide, Related to Figure 4
(A and B) Fluorescence polarization assays as in Figure 4B–4D for OTUB1 (A) and Cezanne2 (B).
(C and D) Alanine scanning mutagenesis of the K11 peptide.
(C) Sequences of mutated ﬂuorescent DUB substrates.
(D) Bar graph representation of graphs shown in Figure 4F. Error bars represent SD from the mean.
Cell 154, 169–184, July 3, 2013 ª2013 The Authors S7Figure S5. Structural Studies on OTUD1, OTUD2, and OTUD3 Reveals a Conserved S1’ Site, Related to Figure 5
(A–C) Close-up view of OTUD1 (A), OTUD2 (B) and OTUD3 (C) with 2jFoj-jFcj electron density contoured at 1s covering catalytic triad residues.
(D) Superposition of OTUD1, OTUD2, OTUD3, OTUD5/DUBA (Huang et al., 2012) and yOtu1 (Messick et al., 2008). Structures are highly similar with low rmsd
values ( 0.8 A ˚ ).
(E) Structure of phosphorylated human OTUD5 bound to a Ub suicide probe (pdb-id 3tmp) (Huang et al., 2012).
(F) 2jFoj-jFcj electron density contoured at 1s covers the isopeptide and peptide bound across the active site of OTUD2.
(G) Arrangement of molecules in the OTUD2 C160A complex with ubiquitinated K11 peptide. Two OTUD2 molecules are present, one of which interacts with two
Ub moieties in S1 and S2 sites. 2jFoj-jFcj electron density contoured at 1s covers the Ub molecules in the complex, indicating that the molecule in the S2 site is
less well ordered. A beige OTUD2 from aneighboring asymmetric unit formsacrystal contactwiththecomplexedOTUD2 molecule, affectingthepeptide binding
site of OTUD2.
(H–J) OTUD2 C160A complex with ubiquitinated K11 peptide (H), the OTUB1 structure with two Ub moieties bound in S1 and S1’ sites (Wiener et al., 2012) (I) and
OTULIN in complex with Met1-linked diUb (J) in identical orientations. Putative S1’ site elements (Cys, His, and V loop C-terminal helix in OTUD2) are indicated.
(K) A His-lop mutation in OTUD3, R
178YGE to LSNG creates a OTU DUB with reduced activity against Lys11-linked diUb. Comparison of a ﬁne time course of
Lys6- and Lys11-linked diUb. Note differences in enzyme concentration used in assays.
S8 Cell 154, 169–184, July 3, 2013 ª2013 The Authorshr
Figure S6. Additional Assays for S2 Site Characterization and Ub Chain Restriction Analysis, Related to Figures 6 and 7
(A) Reactivity of wild-type OTUD2 catalytic domain (aa 147–314), S2 site mutant (MutS2, aa 147–314, I292Q, V295Q), S1 site mutant (MutS1, aa 147–314, AI200-
201DD) and corresponding inactive variants (C160A) against Ub-PA.
(B) Speciﬁcity analysis of OTUD2 MutS2.
(C) DUB assay with constructs in (A) against K11-linked diUb.
(D) Cleavage of triUb substrates as in (B).
(E) Speciﬁcity analysis of OTUD1 using triUb substrates.
(F–H) Western blotted restriction analysis gels (anti-Ub) of GST-TRAF6 assembled free and attached Lys63-linked polyUb (F), autoubiquitinated GST-NEDD4 (G)
and GST-E6AP (H). Compare silver-stained counterparts in Figures 7C–7E.
Cell 154, 169–184, July 3, 2013 ª2013 The Authors S9  1 
Table S1. Crystallization Data Collection and Refinement Statistics,  
Related to Figure 5 and 6 














Data collection statistics           
Beamline  ESRF ID23-1  ESRF ID23-1  ESRF ID29  Diamond I-03  Diamond I-04 
Wavelength (Å)  0.9794  0.9792  0.97627  0.9763  0.9464 
Space Group  I4  P3121  P3212  C2  P6 
Unit Cell (Å)  a = 82.24 
b = 82.24 
c = 103.94 
a = 60.67 
b = 60.67  
c = 86.18 
a = 36.20 
b = 36.20  
c = 211.05 
a = 174.79 
b = 44.22  
c = 84.95 
 = 91.4º 
a = 164.48 
b = 164.48  
c = 44.73 
Resolution (Å)  52.0 – 2.10 





50.0 - 3.03  
(3.19 - 3.03) 
53.84 - 2.35  
(2.43 - 2.35) 
Observed reflections  65317 (9688)  128709 
(18568) 
92022 (13007)  40480 (6177)  177275 
(17419) 
Unique reflections  20153 (2957)  30915 (4562)  23429 (3352)  12691 (1860)  29294 (2827) 
Redundancy  3.2 (3.3)    4.2 (4.1)  3.9 (3.9)  3.2 (3.3)  6.1 (6.2) 
Completeness (%)  99.8 (99.9)  97.2 (99.5)  98.9 (99.1)  97.9 (98.8)  100 (100) 
Rmerge    0.095 (0.530)  0.069 (0.623)  0.041 (0.477)  0.135 (0.441)  0.118 (0.887) 
<I/ I>    8.9 (2.3)    10.5 (2.0)  14.9 (2.1)  7.1 (3.3)  10.0 (1.9) 
Phasing statistics           
Molecular Replacement  Phaser  Phaser  Phaser  Phaser  Phaser 







Refinement statistics           
Reflections in test set  1029  1554  1204  613  1487 
Rcryst  16.2  17.9  17.5  19.4  18.7 
Rfree  20.2  19.5  22.9  25.4  23.7 
Number of groups           
Protein residues  299  175  141  546  485 
Ions and ligand atoms  10  24  0  2  5 
Water  147  131  113  11  231 
Wilson B-factor  25.7  18.3  23.66  42.89  37.2 
RMSD from ideal 
geometry 
         
Bond length (Å)  0.007  0.020  0.005  0.009  0.009 
Bond angles (°)  1.017  2.065  0.916  1.156  1.141 
Ramachandran Plot 
Statistics 
         
In Favoured Regions (%)  292 (99.0)  192 (98.7)  140 (96.6)  516 (96.5)  456 (95.0) 
In Allowed Regions (%)  3 (1.0)  2 (1.1%)  5 (3.5)  19 (3.5)  24 (5.0) 
 Outliers (%)  0 (0)  0 (0)  0 (0)  0 (0)  0 (0) 
 
Values in parentheses are for the highest resolution shell.                                                                        ENSP00000365678_Hsap_/287-481   
 290       300       310       320       330       340       350      
ENSP00000365678_Hsap_/287-481           LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSPTRP00000003995_Ptro_/286-480        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSGGOP00000000728_Ggor_/287-481        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     D     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSMMUP00000012116_Mmul_/286-480        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSTGUP00000001214_Tgut_/5-199          LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       K RF FHI            K    D     E     V       D   P S   AL        DK  RQ G                 C AVY   RL G    Q   Y      H N 
ENSGALP00000030602_Ggal_/7-201          LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       K RF FHI            K    D     E     V       D   P S   AL        DR  RQ G                 C AVY   RP G    Q   Y      H G 
ENSPSIP00000001551_Psin_/6-200          LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       K RF FHI            K    D     D     V           P S   AL        DK  RH G                 C TVY   RL S    Q   Y     HH S 
ENSCAFP00000006263_Cfam_/129-323        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    ER       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ S                 S TVY   SL R    Q   Y      H S 
ENSLAFP00000024360_Lafr_/176-370        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K          E     V       D   P D   AL        DK  RQ N                 S TVY N SL R    Q   Y      H S 
ENSOGAP00000015864_Ogar_/210-404        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    ER       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSBTAP00000056095_Btau_/268-462        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    ER       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S AVY   SL R    Q   Y      H S 
ENSCJAP00000014528_Cjac_/265-459        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H N 
ENSXMAP00000020100_Xmac_/5-199          LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    DKV  Y    ER       R KY YHI            K    D     E     V       D   P N   TR        NK  QE H                 C ATY   AR G    Q   H      E I 
ENSTRUP00000045767_Trub_/27-221         LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    DKV  Y    E        R KY YHI            K    D     E     V       D   P D   TR      T NQ  QE R                 C ATY   GR G    E   H      E N 
ENSGACP00000005044_Gacu_/27-221         LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F     KV  Y    EK       R KY YHI            K    D     E     V       E     NS  TR        NK  QE R                 C ATC   AG R    Q   H      E NA
ENSOANP00000021049_Oana_/48-242         LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    ERL       DK       R KF FHI            R    D     D     V       D   P D   ARH       DR  RQ S                 S AVH   SL R    R   Y      R G 
ENSTNIP00000015745_Tnig_/30-223         LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    DKV  Y    EK       R KY YHI            K    D     E     V       D   P N   TR        NQ  QE H                 C ATY   AR G    E   H      Q N 
ENSGMOP00000019561_Gmor_/20-213         LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    D V  Y    E        R KF F V            R    D     E     I       E     R Q SR      E NA  RE N    Q            C ATS   SG L    R   H      Q SH
ENSMUSP00000100617_Mmus_/260-454        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    ER       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSRNOP00000060310_Rnor_/261-455        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    ER       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ N                 S TVY   SL R    Q   Y      H S 
ENSMODP00000011112_Mdom_/201-395        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKL  Y    EK       R KY FHI            K    D     E     V       D   P D   AL        DK  RQ S                 S AMY   SL P    Q   Y      H G 
ENSLACP00000013142_Lcha_/239-433        LAEV  Q  YL      R   IPDGNCLYRAV     G Q  H  LRE T H IADHL  F    EKI  Y    DK       R KY FHI            K    D     D     V       D   P N   AR        NK  RD Q                 S AVY   AM K    Q   H      E N 
               TT                          TT                          ENSP00000365678_Hsap_/287-481   
 360       370       380       390       400       410          420   
ENSP00000365678_Hsap_/287-481      EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSPTRP00000003995_Ptro_/286-480   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSGGOP00000000728_Ggor_/287-481   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSMMUP00000012116_Mmul_/286-480   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSTGUP00000001214_Tgut_/5-199     EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   LI  A    W      L      NVNI        E P  S           ED  RP I             G     A          G       H     RP        V    ...P  PT  S  
ENSGALP00000030602_Ggal_/7-201     EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   LI  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RP        V    ...P  PT  S  
ENSPSIP00000001551_Psin_/6-200     EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   II  A    W      L      NINI        E P  S           ED  RP I             G     A          G       H     RP        A    ...P  PS  S  
ENSCAFP00000006263_Cfam_/129-323   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSLAFP00000024360_Lafr_/176-370   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   LI  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSOGAP00000015864_Ogar_/210-404   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSBTAP00000056095_Btau_/268-462   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSCJAP00000014528_Cjac_/265-459   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   LI  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSXMAP00000020100_Xmac_/5-199     EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   LI  A    W      L      NVNI        E    S           ED  KP I             S     A          S       H     SL  F     V    ...E  AS  A  
ENSTRUP00000045767_Trub_/27-221    EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   LI  A    W      L      N TV        E P  S           DD  RP I             S     T          S    T  Y     SL        G    ...E  PS  A  
ENSGACP00000005044_Gacu_/27-221    EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   V   LI  A    W             SV V        E P  S           ED  KG V             N     A       H  S     D H     SS        V    ...Q  AS  A  
ENSOANP00000021049_Oana_/48-242    EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   LV  A    W      L       VNI        E P              DD  RP I             A     A          G   D   L     RA     A  S    ...P  GR  S  
ENSTNIP00000015745_Tnig_/30-223    EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W IL   V   LI  A           L      N TI        E P  S           DD  RP I             N     A.         S    T  Y     SL        G    ...Q  PS  A  
ENSGMOP00000019561_Gmor_/20-213    EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W VI   V   LI       W      L      QV V          P  S           E      I             S S   A          S     H H     GAR       V    GDEH NAPADD  
ENSMUSP00000100617_Mmus_/260-454   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        I    ...P  SL  S  
ENSRNOP00000060310_Rnor_/261-455   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     A          G       H     RL        V    ...P  SL  S  
ENSMODP00000011112_Mdom_/201-395   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W LI   V   II  A    W      L      NVNI        E P  S           ED  RP I             A     S          G       H     RL        I    ...P  SL  S  
ENSLACP00000013142_Lcha_/239-433   EGD GEF   A QDG  AGYPEL AM QML     LTTGG   S TV TM HYLG            W II   I   LI  A    W      L      NINI        E P  S           ED  K  I             N     T          S       Y     SL        V    ...A  AM TS  
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ENSP00000365678_Hsap_/287-481    LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSPTRP00000003995_Ptro_/286-480 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSGGOP00000000728_Ggor_/287-481 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSMMUP00000012116_Mmul_/286-480 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSTGUP00000001214_Tgut_/5-199   LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    E   R T V RR   E  KS  V   K  I                               L RVC      A   Q                           ACS            
ENSGALP00000030602_Ggal_/7-201   LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    E   R T V RR   E  KS  V   K  I                               L RVC      A   Q                           ACS            
ENSPSIP00000001551_Psin_/6-200   LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    E   R T V RR   E  KS  M   K  I                               L CEC      A   Q                           TCS            
ENSCAFP00000006263_Cfam_/129-323 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   R T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSLAFP00000024360_Lafr_/176-370 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSOGAP00000015864_Ogar_/210-404 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HCY      N   Q                           ACS            
ENSBTAP00000056095_Btau_/268-462 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   R T V RK   E  KS  I   K  I                               F HSY      T   Q                           ACS            
ENSCJAP00000014528_Cjac_/265-459 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSXMAP00000020100_Xmac_/5-199   LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          VV     P    E   R S M RK   D  KS  A   K  L                               L KRL      D   Q                           GYV            
ENSTRUP00000045767_Trub_/27-221  LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          VL     P    E   R S M RK   E  KS  A   K                                  L KSL      D   H                       S   GCA            
ENSGACP00000005044_Gacu_/27-221  LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AL     P    E     S M R    E  KS  A   R  I                               L ECL      D  SR     Q                     GSA            
ENSOANP00000021049_Oana_/48-242  LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   R T V RK   E  KS  V   K  I                               F RCH      S   Q                           TCS            
ENSTNIP00000015745_Tnig_/30-223  LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          VL     P    E   R S M KR   E  KS  A   K  I                               L KSL      D   H                           GVC            
ENSGMOP00000019561_Gmor_/20-213  LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          VI     P    E       A RR   E  R   A   R  L                               L E.L      D  MQA            A             ...            
ENSMUSP00000100617_Mmus_/260-454 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T I KK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSRNOP00000060310_Rnor_/261-455 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T M RK   E  KS  I   K  I                               F HSY      N   Q                           ACS            
ENSMODP00000011112_Mdom_/201-395 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV     P    D   K T V RK   E  RS  I   K  I                               F HSY      N   Q                           ACS            
ENSLACP00000013142_Lcha_/239-433 LSWLSNGHYD   D    NPEY  WC   Q Q  RDE LA  MA SLS MY EQN                          AV          E   K T V RK   E  KS  A   K  I                               F HPVL     S   Q                           GYS            
α1  β1  α2  η1  α3  α4  η2
α5  α6  β2  β3 
β4  β5 
OTUD1 OTU+UIM                                                                                 ENSP00000326813_Hsap_/132-348   
                                    140                   150       160         
ENSP00000326813_Hsap_/132-348                                                                    V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSPTRP00000003224_Ptro_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSMMUP00000029187_Mmul_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSPPYP00000000289_Pabe_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSGGOP00000006268_Ggor_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSNLEP00000001132_Nleu_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............R....GASSYVRET............LP  T T             Y VV
ENSTSYP00000001619_Tsyr_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TI...............H....GAPSYIRET............LP  T T             Y VV
ENSAMEP00000003810_Amel_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYVRET............LP  G T             Y VV
ENSMPUP00000009801_Mpfu_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYVRET............LP  N T             Y VV
ENSCJAP00000034210_Cjac_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   SL...........TK...............H....GASSYVRET............LP  A T             Y VV
ENSMICP00000007658_Mmur_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYIRET............LP  S T             Y VV
ENSSTOP00000018229_Itri_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   SY...........TK...............H....GAPSYVRET............LP  T T             Y VV
ENSCAFP00000016941_Cfam_/129-345                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   TF...........TK...............H....GAPSYVREP............LP  S T             Y VV
ENSFCAP00000012831_Fcat_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYVRET............LP  S T             Y VV
ENSOCUP00000012332_Ocun_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........SK...............H....GAPSYVRET............LP  S T             Y VV
ENSSSCP00000016602_Sscr_/132-348                                                                 V  DNSCLF                                                                  VL R T PA      TSV Y   AF...........TK...............H....GAPSYVREP............LP  T T             Y VV
ENSPVAP00000010907_Pvam_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYVRET............LP  T T             Y VV
ENSECAP00000007634_Ecab_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........TK...............Y....GAPSYVRET............LP  T T             Y VV
ENSCPOP00000000329_Cpor_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TN...............H....GAPSYVREP............LP  S T             Y VV
ENSOGAP00000003651_Ogar_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TI...............H....GAPSYVRDA............VP  S T             Y VV
ENSRNOP00000031836_Rnor_/127-343                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........SK...............H....GAPSYVRET............LP  T T             Y VV
ENSCHOP00000010764_Chof_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........AK...............H....GAPGSFRET............LP  A M             Y VV
ENSLAFP00000016523_Lafr_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AS...........AK...............H....GAPSYYRES............LP  T A             Y VV
ENSMLUP00000006752_Mluc_/135-351                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TR...............H....GAPGYVRDT............VP  T T             Y VV
ENSVPAP00000010554_Vpac_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   TF...........TK...............L....GAPSYIRET............LP  T T             Y VV
ENSMUSP00000055318_Mmus_/127-343                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........SK...............Y....GAPSYVREA............LP  T T             Y VV
ENSBTAP00000027017_Btau_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........TK...............Y....GAPSYVRET............LP  A M             Y VV
ENSPCAP00000011324_Pcap_/127-343                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........AK...............H....GAPSYYRES............LP  T T             Y VV
ENSDNOP00000003594_Dnov_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   SF...........TK...............H....GAPSSFRET............VP  A T             Y VV
ENSTTRP00000014783_Ttru_/132-348                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AF...........TK...............H....GAPSYIRET............LP  T A             Y VV
ENSETEP00000001730_Etel_/132-348                                                                 V  DNSCLF                                                                  VL R A PA      TSV Y   AF...........AK...............P....GAPSYYREM............LP  T T             Y VV
ENSMODP00000002623_Mdom_/233-449                                                                 V  DNSCLF                                                                  VL R V PA      TSV Y   AV...........TK...............H....GAHTSFREV............LP  T T             Y VV
ENSOANP00000008335_Oana_/88-304                                                                  V  DNSCLF                                                                  VL R V PA      TSV Y   AV...........MK...............H....GAPSSVRDA............LP  S K             F VV
ENSSHAP00000017993_Shar_/138-354                                                                 V  DNSCLF                                                                  EL R V PA      TSV Y   AV...........TE...............H....GADTSFGEV............LP  T T             Y VV
ENSACAP00000013589_Acar_/94-310                                                                  V  DNSCLF                                                                  VL R V PA      TSI Y   IV...........TK...............R....TASNSFREA............LP  A K             Y VV
ENSGALP00000039556_Ggal_/88-302                                                                  V  DNSCLF                                                                  VL R V PA      TSV Y   VV...........AK...............R....TMA..VREA............VP  A R             Y VV
ENSLACP00000021462_Lcha_/88-304                                                                  V  DNSCLF                                                                  VL R V PA      TSV Y   AV...........SK...............I....NADSPIEET............HP  K H             Y VV
ENSXMAP00000017765_Xmac_/87-300                                                                  V  DNSCLF                                                                  VL R V PA      TSV Y   HP............I...............V....KA..PHLEL............SP  A R             N VV
ENSORLP00000021191_Olat_/87-300                                                                  V  DNSCLF                                                                  VL R V PA      TSV Y   QP............V...............V....KA..PRLDA............SP  A R             Y VV
ENSDARP00000003565_Drer_/87-301                                                                  V  DNSCLF                                                                  VV R V PA      TSV Y   QP...........TV...............T....KG..PSFEV............TP  E R             N VM
ENSGACP00000006129_Gacu_/90-303                                                                  V  DNSCLF                                                                  TL R V PV      TSV Y   PP...........AV...............T....KP..PLLDA............SP  A R             Y .V
ENSTRUP00000028592_Trub_/87-325                                                                  V  DNSCLF                                                                  AL R V PA      TSV Y   QS...........SI...............T....KV..PRLEA.....S......SP  A R             F VV
ENSXETP00000037286_Xtro_/88-304                                                                  V  DNSCLF                                                                  TI R V PA      TSI Y   PV...........SK...............T....DLGNWNAPA............QP  V R             Y VV
ENSTNIP00000005743_Tnig_/91-303                                                                  V  DNSCLF                                                                  QL R V PA      TSV Y   QS...........DI...............T....KV..PPLDV............SP  A R             F VV
ENSPMAP00000003678_Pmar_/128-354                                                                 V  DNSCLF                                                                  AE R V PA      TSV Y   AT...........RP...............N....GLPSPRVTA............AP  R H             S AL
ENSCINP00000034086_Cint_/89-296                                                                  V  DNSCLF                                                                  RM R E PA      YSV Y   .......................................TVVE..............P  L K             F AL
FBpp0076867_Dmel_/92-347                                                                         V  DNSCLF                                                                  IL K V PA      TSI F   VPGGTTVEDDEALARRLQAEEEAQLLQETAGGPVAQAADYQLPV.APTESGPNGDFNG  L K             R VL
YFL044C_Scer_/85-301                                                                             V  DNSCLF                                                                  VL V P LD      HAI Y   PPQ..........PK...............P....KRVLKSTEMSIGGSG......EN  S H             A ..
             .......                                                             ENSP00000326813_Hsap_/132-348   
170         180              190       200       210       220       230       240
ENSP00000326813_Hsap_/132-348                          R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSPTRP00000003224_Ptro_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSMMUP00000029187_Mmul_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSPPYP00000000289_Pabe_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSGGOP00000006268_Ggor_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSNLEP00000001132_Nleu_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSTSYP00000001619_Tsyr_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSAMEP00000003810_Amel_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSMPUP00000009801_Mpfu_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSCJAP00000034210_Cjac_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSMICP00000007658_Mmur_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSSTOP00000018229_Itri_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DL S      T  E CD  K D                 C  C   
ENSCAFP00000016941_Cfam_/129-345                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSFCAP00000012831_Fcat_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSOCUP00000012332_Ocun_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LD..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSSSCP00000016602_Sscr_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSPVAP00000010907_Pvam_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CE  K D                 C  C   
ENSECAP00000007634_Ecab_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAEI ASDP  Y E I G  NE       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          EF S      T  E CD  K D                 C  C   
ENSCPOP00000000329_Cpor_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NE       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSOGAP00000003651_Ogar_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDT  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSRNOP00000031836_Rnor_/127-343                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NE       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DL S      T  E CD  R D                 C  C   
ENSCHOP00000010764_Chof_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CE  K D                 C  C   
ENSLAFP00000016523_Lafr_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          EF S      T  E CD  K D                 C  C   
ENSMLUP00000006752_Mluc_/135-351                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIARI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CE  K D                 C  C   
ENSVPAP00000010554_Vpac_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          VL S      T  E CD  K D                 C  C   
ENSMUSP00000055318_Mmus_/127-343                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NE       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          VL S      T  D CD  R D                 C  C   
ENSBTAP00000027017_Btau_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  FIAQI ASDP  Y E I G  NE       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CD  K D                 C  C   
ENSPCAP00000011324_Pcap_/127-343                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NQ       R DT   A  ISILSKFYQ E  VV  E G LN..PACAP.......   R          EF S      T  E CD  K D                 C  C   
ENSDNOP00000003594_Dnov_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E I G  NQ       R DT   A  ISILCKFYQ E  VV  E G LN..PACAP.......   R          DF S      T  E CE  K D                 C  C   
ENSTTRP00000014783_Ttru_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASNP  Y K I G  NQ       R DT   A  ISVLSKFYQ E  VV  E G LN..PACAP.......   H          DF S      T  E CD  K E                 C  C   
ENSETEP00000001730_Etel_/132-348                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  FIAQI ASDP  Y E I G  NE       R DT   A  ISILSKYYQ E  VV  E G LN..PACAP.......   R          EF S      T  E CD  Q D                 C  C   
ENSMODP00000002623_Mdom_/233-449                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAEI ASDP  Y E L G  NQ       R DT   A  ISILSKFYQ E  VV  E G LD..PACAP.......   N          EF C      T  E CD  R D                 C  C   
ENSOANP00000008335_Oana_/88-304                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NQ       R DT   A  VSILSKFYQ E  VV  E G LD..PACAP.......   S          EF C      T  E CD  R D                 C  C   
ENSSHAP00000017993_Shar_/138-354                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAET ASDP  Y E F E  NQ       R DT   A  ISILSKFYQ E  VV  E G LD..PTRAP.......   N          EF C      T  E CE  K D                 C  C   
ENSACAP00000013589_Acar_/94-310                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NQ       R DT   A  VSILSKFYQ E  VV  E G YD..PGCAP.......   N          ES S      T  E CE  R E                 C  C   
ENSGALP00000039556_Ggal_/88-302                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NR       R ET   A  VSILSKFYQ E  VV  E G YD..PGCAP.......   S          EA C      T  E CE  R E                 C  C   
ENSLACP00000021462_Lcha_/88-304                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI LSDP  Y E V G  NQ       R DT   A  ISILSKFYQ E  VV  E G YK..PACVP.......   S          ES S      T  D CN  R D                 C  C   
ENSXMAP00000017765_Xmac_/87-300                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI SSDP  Y E V G  NE       R DT   A  VSILSKFYQ E  VV  E G YD..PACAP.......   S          TA C      T  E CA  K D                 C  C   
ENSORLP00000021191_Olat_/87-300                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI SSDP  Y E V G  NE       R DT   A  VSILSKFYQ E  VV  E G YD..PACAP.......   G          AA C      T  D CA  R D                 C  C   
ENSDARP00000003565_Drer_/87-301                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI ASDP  Y E V G  NE       R DT   A  VSILSKFYQ E  VV  E G YD..PACAS.......   G          TA S      T  E CT  R D                 C  C   
ENSGACP00000006129_Gacu_/90-303                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI SSDP  Y E V G  NE       R DT   A  VSIMSKFYQ E  VV  E G YD..PACAP.......   G          AA S      T  D CA  R D                 C  C   
ENSTRUP00000028592_Trub_/87-325                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQI SSDS  Y E V G  NE       R DT   A  LSILSKFYQ E  VV  E G YD..PACSP.......   G          TA S      T  E CD  R D                 C  C   
ENSXETP00000037286_Xtro_/88-304                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAEI ASDP  Y E V G  NE       R DT   A  VSILSKFYQ E  VV  E G YD..PACAP.......   N          ST C      S  E CT  R E                 C  C   
ENSTNIP00000005743_Tnig_/91-303                        R      V         A L K    Y  WI     WGG IE           I   D  G V                EM  LIAQM SSDP  Y E V G  NE       R DT   A  LSILSKFYQ E  VV  E G YD..PACAP.......   G          AA S      T  Q CE  R G                 C  C   
ENSPMAP00000003678_Pmar_/128-354                       R      V         A L K    Y  WI     WGG IE           I   D  G V                EL  LIASV AGEP  Y E L G  NA       Q DT   A  LSILARFYE E  VA  D P AAAAPAAAATAAGRAR   R          DT S      P  E CR  . E                 C  C   
ENSCINP00000034086_Cint_/89-296                        R      V         A L K    Y  WI     WGG IE           I   D  G L                RL  DIANV RSNP  Y E V G  AD       C SS   G  LSILSKIYQ E  AV  Q R TKNDYPEAK.......   A          EE T      T  E SV  Q D                 V  A   
FBpp0076867_Dmel_/92-347                               R      V         A L K    Y  WI     WGG IE           I   D  G V                MM  IIAQE AADP  Y D V G  NA       K DS   A  VSILSNYYG E  VV  N K DN..EGS.E.......   H          QS N      S  E CA  Q A                 I  D   
YFL044C_Scer_/85-301                                   R      V         A L K    Y  WI     WGG IE           I   D  . I                DL  MVSKE LNNP  F D I D  NK       K ES   A  IGIISDALA A  VV  . G FK..QDSVR.......   E          VK N      P  D AQ  L M                 V  Y   
η1  β1  α1 
α2  α3  α4  α5  β2 
OTUD2 OTU+ZnFENSP00000326813_Hsap_/132-348                            G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSPTRP00000003224_Ptro_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSMMUP00000029187_Mmul_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSPPYP00000000289_Pabe_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSGGOP00000006268_Ggor_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QHNFPD..PDTPPL   SSN...            DE          N 
ENSNLEP00000001132_Nleu_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G N               QRNFPD..PDTPPL   SSN...            DE          N 
ENSTSYP00000001619_Tsyr_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDV Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSAMEP00000003810_Amel_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSMPUP00000009801_Mpfu_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSCJAP00000034210_Cjac_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARKRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSMICP00000007658_Mmur_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G S               QRDFPD..PDTPPL   SSN...            DE          N 
ENSSTOP00000018229_Itri_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRMRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSCAFP00000016941_Cfam_/129-345                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSFCAP00000012831_Fcat_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRVFPD..PDTPPL   SSN...            DE          N 
ENSOCUP00000012332_Ocun_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRDFPD..PDTPPL   SSN...            DE          N 
ENSSSCP00000016602_Sscr_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARSKRQFTDV R              G T               QRVFPD..PDTPPL   SSN...            DE          N 
ENSPVAP00000010907_Pvam_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   AKRKRQFTDV R              G T               QRTFPD..PDTPPL   SSN...            DE          N 
ENSECAP00000007634_Ecab_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PHTPPL   SSN...            DE          N 
ENSCPOP00000000329_Cpor_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G S               QRNFPD..PDTPPL   SCN...            DE          N 
ENSOGAP00000003651_Ogar_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRRRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSRNOP00000031836_Rnor_/127-343                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSCHOP00000010764_Chof_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRDFPD..PDTPPL   SSN...            DE          N 
ENSLAFP00000016523_Lafr_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSMLUP00000006752_Mluc_/135-351                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD V   PL               I       DDIVLVQ LEL   AKRKRQFTDV R              G S               QRNFPD..PDTPPL   SSN...            DE          N 
ENSVPAP00000010554_Vpac_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARSKRQFTDV R              G T               QRVFPD..PNTPPL   SSN...            DE          N 
ENSMUSP00000055318_Mmus_/127-343                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSBTAP00000027017_Btau_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARKKRQFTDV R              G T               HLVFPD..PDTPPL   SSY...            DE          N 
ENSPCAP00000011324_Pcap_/127-343                         G HYD                T F             A   A               TQTVRIDRFGEDV Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARKKRQFTDV H              G T               QRNFPD..PDTPPL   SSN...            DE          N 
ENSDNOP00000003594_Dnov_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARRKRQFTDV R              G T               QRIFPD..PDTPPL   SSN...            DE          N 
ENSTTRP00000014783_Ttru_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLVQ LEL   ARSKRQFTDV R              G T               QRVFPN..PDTPPL   SSN...            DE          N 
ENSETEP00000001730_Etel_/132-348                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDVVLVQ LEL   ARKKRLFTDV R              G T               QRNFPD..PDTPPL   SSN...            EE          N 
ENSMODP00000002623_Mdom_/233-449                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLAQ LEL   ARRKRQFTDV R              G T               QRNFPD..PDSPPL   SSN...            DE          N 
ENSOANP00000008335_Oana_/88-304                          G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLAQ LEL   ARRKRQFTDV R              G T               ERIFCD..PDTPPL   SSN...            DE          N 
ENSSHAP00000017993_Shar_/138-354                         G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDVVLAQ LEL   ARKKRQFTDV R              A P               QRNLPD..PDSPPL   SSN...            EE          N 
ENSACAP00000013589_Acar_/94-310                          G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDIVLAQ MEL   ARRKRQFTDV R              G A               ERKIPN..SDVPPQ   SAS...            DE          N 
ENSGALP00000039556_Ggal_/88-302                          G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDVVLAQ LEL   ARRKRQFTDV R              G T               ERKIPD..SDVPPQ   STT...            DE          N 
ENSLACP00000021462_Lcha_/88-304                          G HYD                T F             A   A               TQTVRIDRFGEDA Y KRVLLIYD I   PL               I       DDVVLAE LEL   ARRKRQFTDV R              G T               QREFPN..SDSPSQ   SAS...            DE          N 
ENSXMAP00000017765_Xmac_/87-300                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               I       DDIILAQ LEL   ARRKRQFTDV R              G H               QKEVPH..SETPPQ   STT...            DE          N 
ENSORLP00000021191_Olat_/87-300                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               I       DDVILAQ LEL   ARRKRQFTDV R              G H               QKETPG..SDSPPQ   STT...            DE          N 
ENSDARP00000003565_Drer_/87-301                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               V       DDVILAQ LEL   ARRKRQFTDV R              G T               QKVLPG..SDVPAQ   STV...            DE          N 
ENSGACP00000006129_Gacu_/90-303                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               I       DDVILAQ LEL   ARRKRQFTDV R              G H               QRETPG..SDAPPL   ATA...            DE          N 
ENSTRUP00000028592_Trub_/87-325                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               I       DDVILAQ LEL   ARRKRQFTDV R              G Q               QRVLPG..SDDPPH   STT...            DD          S 
ENSXETP00000037286_Xtro_/88-304                          G HYD                T F             A   A               TQTVRIDRFGEDS Y KRVLLIYD I   PL               V       DDEALVQ MEL   ARKKRQFTDV Q              G T               QRLFAD..LDMPPM   STT...            DD          N 
ENSTNIP00000005743_Tnig_/91-303                          G HYD                T F             A   A               TQTVRVDRFGEDA Y KRVLLIYD I   PL               I       DDVILAQ LEL   ARRKRQFTDV R              G Q               QNELRG..SDAPPH   STS...            DD          . 
ENSPMAP00000003678_Pmar_/128-354                         G HYD                T F             A   A               TQTLRVDRFGEGS Y RRALLIYD I   PL               L       DDVPLAQ QEL   ARRRRQFTDL R              G A               ELSPVDGAPHRPPR   PTT...            EE          T 
ENSCINP00000034086_Cint_/89-296                          G HYD                T F             A   A               IQTLRVDNYGQNA Y TRIFLLYD I   PM               I       DDVALSN IKV   CHKARLYTDT N              G L               YLDSGN..PSLPTQ   TTS...            EG          A 
FBpp0076867_Dmel_/92-347                                 G HYD                T F             A   A               IQNAIINRFGEDK F LRVFLLFD I   PL               I       ELGVYQQ EQL   AQSSRQYTNV K              N G               YMETS...PSAAPA   PVE...            NE          D 
YFL044C_Scer_/85-301                                     G HYD                T F             A   A               IDAVKIEKFNEDK F NYILILFN I   SL               V       SDDVLTA LQL   LKQTGYSFNT K              . D               TMN......EF..K   NKNQPE            SN          H 
                                                                                 ENSP00000326813_Hsap_/132-348   
  320       330       340                                                       
ENSP00000326813_Hsap_/132-348        C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSPTRP00000003224_Ptro_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSMMUP00000029187_Mmul_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSPPYP00000000289_Pabe_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSGGOP00000006268_Ggor_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSNLEP00000001132_Nleu_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSTSYP00000001619_Tsyr_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSAMEP00000003810_Amel_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSMPUP00000009801_Mpfu_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSCJAP00000034210_Cjac_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSMICP00000007658_Mmur_/132-348     C  C     G      HA  TGH  FG                                                  F LR MI Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSSTOP00000018229_Itri_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSCAFP00000016941_Cfam_/129-345     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSFCAP00000012831_Fcat_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG V  A   D             .......................                        
ENSOCUP00000012332_Ocun_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSSSCP00000016602_Sscr_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSPVAP00000010907_Pvam_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   RE   TS  EV                                                 T       KG T  A   E             .......................                        
ENSECAP00000007634_Ecab_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSCPOP00000000329_Cpor_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSOGAP00000003651_Ogar_/132-348     C  C     G      HA  TGH  FG                                                  F LR MI Q  L  Q EAR   KE   TN  EV                                                 T       KG I  A   E             .......................                        
ENSRNOP00000031836_Rnor_/127-343     C  C     G      HA  TGH  FG                                                  F LR ML Q  L  Q EAR   RE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSCHOP00000010764_Chof_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSLAFP00000016523_Lafr_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TS  EV                                                 T       KG T  A   D             .......................                        
ENSMLUP00000006752_Mluc_/135-351     C  C     G      HA  TGH  FG                                                  F LR MI Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSVPAP00000010554_Vpac_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG I  A   D             .......................                        
ENSMUSP00000055318_Mmus_/127-343     C  C     G      HA  TGH  FG                                                  F LR MI Q  L  Q EAR   RE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSBTAP00000027017_Btau_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSPCAP00000011324_Pcap_/127-343     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   RE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSDNOP00000003594_Dnov_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV H  L  Q EAR   KE   TS  EV                                                 T       KG T  A   D             .......................                        
ENSTTRP00000014783_Ttru_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  H EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSETEP00000001730_Etel_/132-348     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   D             .......................                        
ENSMODP00000002623_Mdom_/233-449     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSOANP00000008335_Oana_/88-304      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  A   E             .......................                        
ENSSHAP00000017993_Shar_/138-354     C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KN   TN  EV                                                 I       KG R  A   E             .......................                        
ENSACAP00000013589_Acar_/94-310      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  V   E             .......................                        
ENSGALP00000039556_Ggal_/88-302      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 T       KG T  V   E             .......................                        
ENSLACP00000021462_Lcha_/88-304      C  C     G      HA  TGH  FG                                                  F LC MV Q  L  Q EAR   ME   AN  EV                                                 T       KG V  G   E             .......................                        
ENSXMAP00000017765_Xmac_/87-300      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 A       TG V  K   E             .......................                        
ENSORLP00000021191_Olat_/87-300      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 A       TG V  K   E             .......................                        
ENSDARP00000003565_Drer_/87-301      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 A       TG V  K   E             .......................                        
ENSGACP00000006129_Gacu_/90-303      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q EAR   KE   TN  EV                                                 A       TG V  K   E             .......................                        
ENSTRUP00000028592_Trub_/87-325      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  E EAR   KV   TN  ED                                                 D       TG V  K   Q             LIHSCLKCNTQSPTVTPRVCVFR                        
ENSXETP00000037286_Xtro_/88-304      C  C     G      HA  TGH  FG                                                  F LR MV Q  L  Q AAR   KE   TN  EV                                                 A       KG T  S   D             .......................                        
ENSTNIP00000005743_Tnig_/91-303      C  C     G      HA  TGH  FG                                                  F LR LV Q  L  Q EAR   KE   TS  EV                                                 A       TG .  K   E             .......................                        
ENSPMAP00000003678_Pmar_/128-354     C  C     G      HA  TGH  FG                                                  F LR LA Q  L  Q EAQ   EE   LN  EV                                                 A       KG T  R   R             .......................                        
ENSCINP00000034086_Cint_/89-296      C  C     G      HA  TGH  FG                                                  F LR LT N  L  Q GAQ   KE   GN  EV                                                 N       TL S  T   K             .......................                        
FBpp0076867_Dmel_/92-347             C  C     G      HA  TGH  FG                                                  F LR MQ D  L  Q QAQ   KQ   KN  EI                                                 T       VR V  V   E             .......................                        
YFL044C_Scer_/85-301                 C  C     G      HA  TGH  FG                                                  A IK NT Q  F  E EVA   ES   VD  QN                                                 Q       MT V  R   R             R......................                        
OTUD2 OTU+ZnF        .                                                         TT   ENSP00000364261_Hsap_/52-209   
        60        70         80        90       100       110         
ENSP00000364261_Hsap_/52-209             L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSGGOP00000022570_Ggor_/52-207          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSPTRP00000000483_Ptro_/52-209          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSNLEP00000009609_Nleu_/51-208          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSMMUP00000014098_Mmul_/51-208          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSMPUP00000016035_Mpfu_/52-209          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSCPOP00000013583_Cpor_/52-209          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         V 
ENSMLUP00000011280_Mluc_/50-205          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  QH     D  IKQ E         I 
ENSCAFP00000022267_Cfam_/52-209          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P ECVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSPVAP00000002438_Pvam_/40-198          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANS  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    M               .N      G     H  N  KH     D  IKQ E         I 
ENSTTRP00000004202_Ttru_/52-209          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSRNOP00000023143_Rnor_/51-208          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IRQ E         I 
ENSLAFP00000006943_Lafr_/50-207          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  RH     D  VKQ G         I 
ENSMUSP00000095441_Mmus_/51-208          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IRQ E         I 
ENSOANP00000008656_Oana_/58-215          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFLS    .               .N      G     H  S  KH     D  IRQ E         I 
ENSMODP00000019844_Mdom_/49-206          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ D         I 
ENSBTAP00000054148_Btau_/52-207          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  V  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IKQ E         I 
ENSOCUP00000017365_Ocun_/52-210          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V FM     D         P EFAS    .               CN      G     H  N  KH     D  VRQ E         V 
ENSLACP00000021192_Lcha_/47-205          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QVM  KLREV       LFRAL DQLEG SL  L  RQE V YM     D         P EFVS    .               .N      G     H  N  KH     D  IQH E         V 
ENSGALP00000022882_Ggal_/34-193          L   GL     PGDG  C               H      T       R  FEPFVEDD       LARQ  RAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P GGGG    .               .N      G     H  N  RH     E  IKQ E         V 
ENSDARP00000037518_Drer_/46-200          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  G  HL     H  RTH N         V 
ENSTGUP00000017330_Tgut_/35-194          L   GL     PGDG  C               H      T       R  FEPFVEDD       LAGQ  RAL  KLREV       LFRAL DQLEG SR  A  RQE V FM     D         P HSGG    .               .N      G     H  N  RH     Q  LRQ G         V 
ENSONIP00000011613_Onil_/47-202          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  G  RL     D  TSH Q         V 
ENSTNIP00000008207_Tnig_/47-199          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  G  RL     Q  MSH Q         V 
ENSXMAP00000012635_Xmac_/47-202          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EYVS    .               .N      G     H  G  RL     Q  MSH Q         V 
ENSTRUP00000018014_Trub_/47-199          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE I YM     D         P EFVS    .               .N      G     H  G  RL     Q  MTH Q         V 
ENSGACP00000006632_Gacu_/47-200          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLEG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  G  RL     Q  MSH Q         V 
ENSORLP00000000334_Olat_/47-202          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  QAL  KLREV       LFRAL DQLQG SR  L  RQE V YM     D         P EFVS    .               .N      G     H  D  RL     H  TSH Q         V 
ENSXETP00000062851_Xtro_/46-200          L   GL     PGDG  C               H      T       R  FEPFVEDD       FANQ  QVL  RVREV       FNLLY RGVWK GK  S  GTK V QV     L         P EFVS    .               .C      D     R  W  GP     G  F.H L         V 
ENSCINP00000034258_Cint_/34-192          L   GL     PGDG  C               H      T       R  FEPFVEDD       FSNQ  ATL  TLKDI       LFRAL DQLEG SR  L  REE V YM     D         S NYAG    .               .N      A     N  R  HH     R  VEH A         C 
                                   TT                                  ENSP00000364261_Hsap_/52-209   
120       130       140       150       160       170       180         
ENSP00000364261_Hsap_/52-209    F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  E SSV        Y E       I
ENSGGOP00000022570_Ggor_/52-207 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  E SSV        Y E       I
ENSPTRP00000000483_Ptro_/52-209 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  E SSV        Y E       I
ENSNLEP00000009609_Nleu_/51-208 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SSV        Y E       I
ENSMMUP00000014098_Mmul_/51-208 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SSV        Y E       I
ENSMPUP00000016035_Mpfu_/52-209 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  E SSV        C E       L
ENSCPOP00000013583_Cpor_/52-209 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SSV        Y E       I
ENSMLUP00000011280_Mluc_/50-205 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SSV        Y E       I
ENSCAFP00000022267_Cfam_/52-209 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  E SSV        C E       L
ENSPVAP00000002438_Pvam_/40-198 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  G SNG        Y E       I
ENSTTRP00000004202_Ttru_/52-209 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   QE     R     D   R   EK  A    P               H  N       A   Q R  D SNV        Y E       V
ENSRNOP00000023143_Rnor_/51-208 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SSA        Y E       I
ENSLAFP00000006943_Lafr_/50-207 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SNV        Y E       I
ENSMUSP00000095441_Mmus_/51-208 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S SK   F           N QL       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D GST        Y E       I
ENSOANP00000008656_Oana_/58-215 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QM       N PL     T K   RE     R     D   R   EK  A    P               H  N       A   Q R  D SNV        Y E       I
ENSMODP00000019844_Mdom_/49-206 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QM       N PL     T K   RE     R     D   R   EK  S    P               H  N       A   Q R  D ANV        Y E       I
ENSBTAP00000054148_Btau_/52-207 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T R   RE     R     D   R   EK  A    P               H  N       A   Q R  D SNG        H E       L
ENSOCUP00000017365_Ocun_/52-210 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V S AK   F           N QL       N PL     T K   RE     R     D   R   EK  A    A               H  N       A   Q R  D SNG        Y E       I
ENSLACP00000021192_Lcha_/47-205 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V N AK   F           I QV       N PL     T K   RE     R     D   R   DK  S    P               N  N       A   Q R  D LNA        Y E       V
ENSGALP00000022882_Ggal_/34-193 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V N AK   F           N QM       D PL     T K   RE     R     D   R   EK  T    P               N  N       A   Q Q  D SNV        H E       I
ENSDARP00000037518_Drer_/46-200 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QL       N PL     T K   RE     R     D   K   EK  T    Q               Q  K       A   E K  E PSC        Y D       T
ENSTGUP00000017330_Tgut_/35-194 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V N AK   F           N QL       N PL     T R   RE     R     D   R   DK  A    P               N  N       T   Q R  D SDA        H E       L
ENSONIP00000011613_Onil_/47-202 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QV       N PL     S K   RE     R     D   R   AQ  A    P               Q  K       T   E N  E QVC        Y D       I
ENSTNIP00000008207_Tnig_/47-199 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QV       N PL     S K   RE     R     D   R   TQ  S    P               Q  K       M   E N  E QVC        Y D       T
ENSXMAP00000012635_Xmac_/47-202 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N AQ   F           S QV       N PL     V K   RE     R     D   R   PQ  S    S               Q  K       A   E N  E QAC        Y D       V
ENSTRUP00000018014_Trub_/47-199 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QV       N PL     S K   RQ     R     D   R   SQ  S    P               Q  K       M   E N  E QVC        Y D       M
ENSGACP00000006632_Gacu_/47-200 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QV       N AL     A K   RE     R     D   R   SQ  S    P               Q  K       T   E N  E EVC        Y D       T
ENSORLP00000000334_Olat_/47-202 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       L N SQ   F           S QV       N PL     S K   RE     R     D   R   VQ  S    P               Q  K       T   E N  E QGC        Y D       L
ENSXETP00000062851_Xtro_/46-200 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V N AK   F           N QV       N PL     S K   RE     R     D   R   DR  A    S               N  N       N   H R  D ADS        Y E       I
ENSCINP00000034258_Cint_/34-192 F  H   L   GT AGNDAIVAFAR     VVIHQL    W I G        LHIAY  G HY SVR       V K RK   Y           N GV       N PM     N R   RQ     H     S   K   ND  Y    D               N  N       A   T N  E SR.        N D       L
                                                                       ENSP00000364261_Hsap_/52-209   
190       200                                                           
ENSP00000364261_Hsap_/52-209     D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSGGOP00000022570_Ggor_/52-207  D    P                                                                   SE  A L                                                             N N  A  H QTD....M.LHQD                                               
ENSPTRP00000000483_Ptro_/52-209  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSNLEP00000009609_Nleu_/51-208  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSMMUP00000014098_Mmul_/51-208  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSMPUP00000016035_Mpfu_/52-209  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSCPOP00000013583_Cpor_/52-209  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QI.LHQD                                               
ENSMLUP00000011280_Mluc_/50-205  D    P                                                                   SE  A L                                                             N N  A  H QTD....I.LHQD                                               
ENSCAFP00000022267_Cfam_/52-209  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSPVAP00000002438_Pvam_/40-198  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSTTRP00000004202_Ttru_/52-209  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSRNOP00000023143_Rnor_/51-208  D    P                                                                   SE  A L                                                             N N  A  H LTDF..QM.LHQD                                               
ENSLAFP00000006943_Lafr_/50-207  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSMUSP00000095441_Mmus_/51-208  D    P                                                                   SE  A L                                                             N N  A  H LTDF..QM.LHQD                                               
ENSOANP00000008656_Oana_/58-215  D    P                                                                   SE  A L                                                             N N  A  H QTEF..QM.LSKD                                               
ENSMODP00000019844_Mdom_/49-206  D    P                                                                   SE  A L                                                             N N  A  H QTEF..QM.LNKD                                               
ENSBTAP00000054148_Btau_/52-207  D    P                                                                   SE  A L                                                             N N  A  R QTE....M.LHQD                                               
ENSOCUP00000017365_Ocun_/52-210  D    P                                                                   SE  A L                                                             N N  A  H QTDF..QM.LHQD                                               
ENSLACP00000021192_Lcha_/47-205  D    P                                                                   SE  A L                                                             S N  S  H KME..DGFHLMRS                                               
ENSGALP00000022882_Ggal_/34-193  D    P                                                                   SE  A L                                                             N D  A  Y RMEDTELM.LSKN                                               
ENSDARP00000037518_Drer_/46-200  D    P                                                                   SE  A L                                                             G N  N  H RIE....S.LNN.                                               
ENSTGUP00000017330_Tgut_/35-194  D    P                                                                   SE  A L                                                             S D  A  C RMEVGCAM.LCKN                                               
ENSONIP00000011613_Onil_/47-202  D    P                                                                   SE  A L                                                             G N  S  Q RIE....N.MQNS                                               
ENSTNIP00000008207_Tnig_/47-199  D    P                                                                   SE  T L                                                             G N  S  Q RVE....P....S                                               
ENSXMAP00000012635_Xmac_/47-202  D    P                                                                   SE  A L                                                             G N  S  Q RIE....T.LQNS                                               
ENSTRUP00000018014_Trub_/47-199  D    P                                                                   SE  A L                                                             G N  S  Q RVE....P....S                                               
ENSGACP00000006632_Gacu_/47-200  D    P                                                                   SE  A L                                                             G N  S  Q RIE....N.S..Q                                               
ENSORLP00000000334_Olat_/47-202  D    P                                                                   SE  A L                                                             G N  S  Q RIE....N.LQRS                                               
ENSXETP00000062851_Xtro_/46-200  D    P                                                                   AE  A L                                                             N N  M  N QTE....M.LSKD                                               
ENSCINP00000034258_Cint_/34-192  D    P                                                                   TD  T I                                                             T D  G  N KLTIQ.SKHENKS                                               
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